Preparation of psilocybin, different polymorphic forms, intermediates and formulations, and their use

JP2024069473A5Active Publication Date: 2024-11-07COMPASS PATHFINDER LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024040039
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-10
Filing Date
2024-03-14
Publication Date
2024-11-07
Estimated Expiration
2038-10-09

AI Technical Summary

Technical Problem

Existing methods for producing psilocybin are limited in scale, purity, and consistency, making it challenging to meet the requirements for large-scale clinical trials and commercial applications, particularly in the treatment of treatment-resistant depression.

Method used

The development of crystalline psilocybin polymorphs A and A', characterized by specific XRPD and DSC patterns, ensuring high chemical purity and stability, achieved through a controlled water crystallization process.

Benefits of technology

The method produces psilocybin in high purity and consistent polymorphic forms, suitable for large-scale clinical use, addressing the challenges of batch-to-batch consistency and stability.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide methods of treating diseases.SOLUTION: This invention relates to the large-scale production of psilocybin for use in medicine. More specifically, this invention relates to a method of obtaining high-purity crystalline psilocybin, particularly, in the form of Polymorph A. This invention further relates to a method for producing psilocybin, intermediates in the production thereof, and formulations containing psilocybin. The large scale means producing batches of psilocybin with a weight greater than 10 g, preferably greater than 100 g, further preferably greater than 250 g and up to, and above, Kg levels.SELECTED DRAWING: Figure 7A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the large-scale production of psilocybin for use in medicine.

[0002] By large scale it is meant producing batches of psilocybin having weights of greater than 10 g, more preferably greater than 100 g, more preferably greater than 250 g, as well as up to and above the Kg level.

[0003] The present invention relates to the use of psilocin intermediates, including but not limited to, different polymorphic forms of psilocybin, including isomorphic variants, and methods for treating depression, including, but not limited to, the use of psilocybin alone or in combination with psychological support, which may be provided digitally, specifically ... th The present invention also relates to the production of formulations thereof for use in medicine for the treatment of treatment-resistant depression as defined in the US 2003 / 0123211 A1. [Background technology]

[0004] Psilocybin was first synthesized by Sandoz in 1958 (see GB Patent No. 912714 and US Patent No. 3,075,992) and was widely available as a research chemical until the mid-1960s.

[0005] The plant-based hallucinogen, psilocybin, has been used as a psychotherapeutic adjunct for the treatment of mood disorders and alcohol-related disorders, and three clinical trials have recently reported the use of psilocybin for depressive symptoms.

[0006] Griffiths et al. 2016;J Psychopharmacol 30(12):1181-1197;

[0007] Ross et al. 2016; J Psychopharmacol 30(12):1165-1180; and

[0008] Carhart-Harris et al. 2016, Lancet Psychiatry 3(7):619-627.

[0009] There are a limited number of ways to produce psilocybin, including:

[0010] J Nat Prod 2003,66,885-887;

[0011] Helv Chim Acta 1959,42,2073-2103;

[0012] Experientia 1958,15,397-399; and

[0013] Synthesis 1999, 935-938.

[0014] Based on this literature, the applicant considered that the process disclosed in J Nat Prod 2003, 66, pp. 885-887 (hereinafter JNP) is the most suitable process for development into a commercial scale process.

[0015] The process disclosed therein produced quantities in the order of 10 g and consisted of six steps numbered (i) to (vi).

[0016] As with Applicant's method, steps ii and iii are discussed below as a single step (step 2), and the JNP method is reproduced as Figure 1 herein.

[0017] Step 1(i) involved reacting 4-hydroxyindole ("3") with acetic anhydride (AcO) in pyridine and anhydrous dichloromethane (CHCl) at 0° C. Water was added, the mixture was evaporated, and the resulting concentrate was dissolved in ethyl acetate, washed with water and saturated sodium chloride, the organic phase was dried over sodium sulfate, and evaporated to give 4-acetylindole ("4"), which was collected by filtration and washed with water and ethyl acetate.

[0018] Step 2 (ii and iii), a two-step acylation (ii)-amidation step (iii), involved (ii) forming 3-dimethylaminooxalyl-4-acetylindole ("6") by reacting 4-acetylindole ("4") with oxalyl chloride ((COCl)2) in anhydrous diethyl ether, stirring, adding n-hexane, maintaining at -20°C, and producing intermediate 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate ("5"), which was isolated by filtration. This intermediate was dissolved in anhydrous tetrahydrofuran (THF) and reacted with dimethylamine ((CH3)2NH) in tetrahydrofuran and pyridine. Due to solidification, anhydrous ether was added, and the reaction product was isolated by filtration and washed with n-hexane, ethyl acetate, and water to give 3-dimethylaminooxalyl-4-acetylindole ("6").

[0019] Step 3(iv) involved the formation of psilocin ("1") by reacting 3-dimethylaminooxalyl-4-acetylindole ("6") with lithium aluminum hydride (LiAlH4) in anhydrous THF under an argon atmosphere. After refluxing and cooling, anhydrous sodium sulfate was added, followed by a solution of sodium sulfate and then anhydrous sodium sulfate. The reaction mixture was diluted with ethyl acetate and quickly concentrated in vacuo, and the resulting psilocin crystals were washed briefly with methanol.

[0020] Step 4(v) involved the formation of benzyl[2-(4-oxindole-3-yl)ethyl]dimethylammonio-4-O-benzylphosphate ("8") by reacting psilocin dissolved in anhydrous THF with n-butyllithium (n-BuLi) in n-hexane at -78°C and tetrabenzylpyrophosphate [(BnO)2PO]2O, warming the reaction to 0°C, and monitoring the production of intermediate dibenzyl 3-[(2-dimethylamino)ethyl]-1H-indol-4-ylphosphate ("7"). Upon checking for the presence of "7", aminopropyl silica gel was added, the mixture was diluted with ethyl acetate, filtered through a Celite pad by suction, and the filtrate was concentrated in vacuo, redissolved in CHCl2, and the precipitate collected by filtration.

[0021] Step 5(vi) involved the formation of psilocybin ("2") by reaction of ("8") with hydrogen (H2) in methanol (MeOH) using a palladium-charcoal catalyst (Pd / C). Due to product precipitation, water was added and the appearance of psilocybin ("8"), its mono-debenzylated derivative, was monitored by filtering the reaction solution through a Celite pad. The product was collected by filtration and washed with ethanol to give a white needle-like crystal form having a melting point of 190°C-198°C.

[0022] Unlike many methods such as JNP's, which use non-aqueous solvents such as methanol or ethanol, Experientia 1958, 15, 397-399 used a single recrystallization from water to obtain psilocybin from mushroom extracts. The teaching was to use boiling water to dissolve the starting material, which was obtained on a small scale by chromatography, and the resulting high vacuum dried material was described as melting indefinitely between 185 and 195 °C. , showing a weight loss of 25.4%, suggesting a distinct difference in purity and morphology from that obtained by applicant.

[0023] During the development of the synthesis to produce psilocybin, applicants performed multiple hydrogenation reactions on the 5 g scale, and different crystalline forms of psilocybin were obtained. The first hydrogenation reaction gave Hydrate A (JCCA2157E), which exhibited the XRPD diffractogram shown in FIG. 7d and the DSC and TGA thermograms shown in FIG. 8d. The DSC shows an endotherm at about 97° C., coincident with a weight loss in the TGA suggesting dehydration, and an endothermic event with an onset temperature of about 216° C., which was estimated to be melting. Another hydrogenation reaction gave an ethanol solvate (JCCA2158D), which exhibited the same XRPD (FIG. 7e), DSC (FIG. 8e), TGA (FIG. 8e) and DSC (FIG. 8e). 1 When analyzed by H NMR, it showed 11% trapped ethanol. The DSC thermogram shows an endotherm with an onset of about 154° C. that appeared to be melting, which coincided with a weight loss of about 13% in the TGA. In another experiment conducted during development, the applicant performed a crystallization of psilocybin. Rather than staying in solution in hot water to allow for a polish filtration step, precipitation occurred at high temperatures (>90° C.). The solid formed did not redissolve upon further heating or addition of more water. Upon cooling and isolation of the solid (CB646E), an XRPD was performed. The XRPD diffractogram (FIG. 7f) suggested mixed phases of polymorph A′ (JCCA2160-F-D4) and polymorph B (JCCA2160-F-TM2-C5). These findings highlight the importance of developing methods capable of consistently producing desired crystalline forms, and therefore Applicant undertook experiments to determine which of these forms are in a position to produce chemically pure psilocybin in a controlled form suitable for use in medicine.

[0024] For clinical trials, any new active substance (NAS) should be capable of large-scale production (typically batches of 100 g or more, more typically 250 g or more, more preferably 500 g or more, up to kg or more) depending on the amount of active substance to be administered to human subjects. The new active substance should also be chemically pure, well defined, and stable on storage.

[0025] Additionally, any manufacturing method must be easily reproducible and provide batch-to-batch consistency.

[0026] It is a primary object of the present invention to provide a consistent polymorphic form of psilocybin for administration to human subjects.

[0027] It is another object of the present invention to provide chemically pure psilocybin in a consistent polymorphic form for administration to human subjects.

[0028] Because pure psilocybin must be produced on a scale for commercial use, it is a further objective to provide chemically pure psilocybin in large batch quantities.

[0029] It is a further object of the present invention to provide a method for crystallizing psilocybin in a desired polymorphic form. It is a further object of the present invention to provide a scalable process for producing psilocybin from psilocin or 4 hydroxyindole.

[0030] In developing a suitable methodology, the applicant experienced numerous problems and difficulties that had to be overcome. The problems identified at each step were overcome and the present invention, used alone or in combination, This is a separate and independent objective. It is a further object of the present invention to formulate the psilocybin of the present invention in a form suitable for administration to a human subject and to use it in medicine, either alone or in combination with a digital health product or digital solution, in particular in the treatment of central nervous system disorders (CNS), and more particularly, but not exclusively, in the treatment of depression, in particular drug-resistant depression. [Prior art documents] [Patent documents]

[0031] [Patent Document 1] British Patent No. 912714 [Patent Document 2] U.S. Pat. No. 3,075,992 [Non-patent literature]

[0032] [Non-Patent Document 1] Griffiths et al. 2016;J Psychopharmacol 30(12):1181-1197 [Non-Patent Document 2] Ross et al. 2016; J Psychopharmacol 30(12):1165-1180 [Non-Patent Document 3] Carhart-Harris et al. 2016, Lancet Psychiatry3(7):619-627 [Non-Patent Document 4] J Nat Prod 2003,66,885-887 [Non-Patent Document 5] Helv Chim Acta 1959,42,2073-2103 [Non-Patent Document 6] Experientia 1958,15,397-399 [Non-Patent Document 7] Synthesis 1999,935-938 Summary of the Invention [Means for solving the problem]

[0033] According to a first aspect of the present invention, there is provided crystalline psilocybin in the form of polymorph A or polymorph A′, characterized by one or more of the following: a. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 degrees 2θ ± 0.1 degrees 2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ (further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ); c. An XRPD diffractogram substantially as depicted in Figure 7a or Figure 7b; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as illustrated in FIG. 8a or FIG. 8b. Polymorph A

[0034] According to preferred embodiments of the present invention, there is provided crystalline psilocybin in the form of polymorph A, characterized by one or more of the following: a. peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5°2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5 °2θ ± 0.1 °2θ (further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ); c. An XRPD diffractogram substantially as depicted in Figure 7a; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as illustrated in FIG. 8a.

[0035] The peak at 17.5°2θ±0.1°2θ has a relative intensity of at least 5%, preferably at least 6%, more preferably at least 7%, 8%, up to 9%, at least 10% compared to the peak at 14.5°2θ±0.1°2θ.

[0036] In one embodiment, psilocybin polymorph A exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 1. In one embodiment, crystalline psilocybin polymorph A described herein comprises at least three peaks (±0.1° 2θ) of Table 1. In some embodiments, crystalline psilocybin polymorph A described herein comprises at least four peaks (±0.1° 2θ) of Table 1. In some embodiments, crystalline psilocybin polymorph A described herein comprises at least five peaks (±0.1° 2θ) of Table 1. In some embodiments, crystalline psilocybin polymorph A described herein comprises at least six peaks (±0.1° 2θ) of Table 1. In some embodiments, crystalline psilocybin polymorph A described herein comprises at least eight peaks (±0.1° 2θ) of Table 1. In some embodiments, the crystalline psilocybin polymorph A described herein contains at least 10 peaks (±0.1 °2θ) of Table 1. In some embodiments, the crystalline psilocybin polymorph A described herein contains at least 15 peaks (±0.1 °2θ) of Table 1. The peak at about 17.5 °2θ ±0.1 °2θ distinguishes psilocybin polymorph A from polymorph A' in which this peak is absent or substantially absent (i.e., has a relative intensity of less than 2%, more preferably less than 1%, compared to the peak at 14.5 °2θ ±0.1 °2θ).

[0037] [Table 1]

[0038] In one embodiment, crystalline psilocybin polymorph A is characterized by XRPD diffractogram peaks at 11.5, 12.0, 14.5, and 17.5 °2θ±0.1 °2θ. In another embodiment, crystalline psilocybin polymorph A is characterized by at least one additional peak occurring at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ±0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph A is further characterized by at least two additional peaks occurring at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph A is further characterized by at least three additional peaks occurring at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ. In a further embodiment, the crystalline psilocybin polymorph A exhibits an XRPD diffractogram substantially identical to the XRPD diffractogram depicted in Figure 7a.

[0039] In one embodiment, crystalline psilocybin polymorph A is characterized by XRPD diffractogram peaks at 14.5 and 17.5 °2θ ± 0.1 °2θ, where the peak at 17.5 °2θ has an intensity that is at least 5%, more preferably at least 6%, at least 7%, to at least 8%, at least 9%, to at least 10% of the intensity of the peak at 14.5 °2θ.

[0040] In one embodiment, crystalline psilocybin polymorph A is absent or substantially absent of the XRPD diffractogram peak at 10.1. By substantially absent, it is meant that any XRPD diffractogram peak at 10.1 is less than 2%, such as less than 1%, of the intensity of the peak at 14.5° 2θ, or is not detectable in the XRPD diffractogram.

[0041] In one embodiment, the crystalline psilocybin polymorph A is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C. In another embodiment, the crystalline psilocybin polymorph A is further characterized by an endothermic event in the DSC thermogram having an onset temperature of 145-165° C., such as 145-160° C., or such as 145-155° C. In another embodiment, the crystalline psilocybin polymorph A is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C., and an endothermic event in the DSC thermogram having an onset temperature of 145-165° C., such as 145-160° C., or such as 145-155° C. In yet another embodiment, crystalline psilocybin polymorph A exhibits a DSC thermogram substantially identical to the DSC thermogram of Figure 8a.

[0042] In another embodiment, the crystalline psilocybin polymorph A is characterized by having a water content of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, or such as less than 0.1% w / w. Those skilled in the art will know methods for measuring the water content of a compound, such as Karl Fischer titration. In one embodiment, the crystalline psilocybin polymorph A is characterized by having a loss of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, such as less than 0.1% w / w in a TGA thermogram at ambient temperature, such as about 25° C. to 200° C. In one embodiment, the crystalline psilocybin polymorph A loses less than 2% by weight, such as less than 1% by weight, such as less than 0.5% by weight in a loss on drying test. The loss on drying test is performed at 70° C.

[0043] In one embodiment, the crystalline psilocybin polymorph A is a highly pure crystalline form of polymorph A, e.g., the psilocybin comprises at least 90% by weight, such as 95% by weight, such as 99% by weight, for example 99.5% by weight of polymorph A.

[0044] In one embodiment, crystalline psilocybin polymorph A is a white to off-white solid.

[0045] In another embodiment, the crystalline psilocybin polymorph A is chemically pure, e.g., The psilocybin has a chemical purity of greater than 97%, such as greater than 98%, or such as greater than 99% by HPLC. In one embodiment, the crystalline psilocybin polymorph A is 31 In one embodiment, crystalline psilocybin polymorph A has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % by HPLC. In one embodiment, crystalline psilocybin polymorph A has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % by HPLC. In one embodiment, crystalline psilocybin polymorph A has a chemical purity of greater than 1 area %, more preferably less than 0.5 area %, by HPLC. In one embodiment, crystalline psilocybin polymorph A does not contain psilocin at a level of greater than 1 area %, more preferably less than 0.5 area %, by HPLC. In one embodiment, crystalline psilocybin polymorph A has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % ... 31 It does not contain phosphate at a level of greater than 1% by weight, more preferably less than 0.5% by weight, as measured by P NMR. In one embodiment, the crystalline psilocybin polymorph A has a chemical assay of at least 95% by weight, such as at least 96% by weight, or such as at least 98% by weight. Polymorph A'

[0046] In accordance with another embodiment of the present invention, there is provided crystalline psilocybin polymorph A' characterized by one or more of the following: a. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ (provided that the peak at 17.5 °2θ ± 0.1 °2θ is absent or substantially absent); b. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ (provided that the peak at 17.5 °2θ ± 0.1 °2θ is absent or substantially absent, and further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ); c. An XRPD diffractogram substantially as depicted in Figure 7b; or d. An endothermic event in a DSC thermogram with an onset temperature of 205-220° C., substantially as illustrated in FIG. 8b.

[0047] Substantially no peak at 17.5°2θ±0.1°2θ means that this peak, if present, has a relative intensity of less than 5%, more preferably less than 4%, less than 3%, to 2%, 1% or less, compared to the peak at 14.5°2θ±0.1°2θ.

[0048] In one embodiment, psilocybin polymorph A' exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 2. In one embodiment, the crystalline psilocybin polymorph A' described herein comprises at least three peaks in Table 2 (±0.1° 2θ), but is absent or substantially absent of a peak at 17.5° 2θ ±0.1° 2θ. In some embodiments, the crystalline psilocybin polymorph A' described herein comprises at least four peaks in Table 2 (±0.1° 2θ), but is absent or substantially absent of a peak at 17.5° 2θ ±0.1° 2θ. In some embodiments, the crystalline psilocybin polymorph A' described herein comprises at least five peaks in Table 2 (±0.1° 2θ), but is absent or substantially absent of a peak at 17.5° 2θ ±0.1° 2θ. In certain embodiments, the crystalline psilocybin polymorph A' described herein contains at least 6 peaks in Table 2 (±0.1° 2θ) but is absent or substantially absent of a peak at 17.5° 2θ ±0.1° 2θ. In certain embodiments, the crystalline psilocybin polymorph A' described herein contains at least 8 ... Psilocybin polymorph A' contains at least 10 peaks (±0.1 °2θ) of Table 2, but is absent or substantially absent of a peak at 17.5 °2θ ±0.1 °2θ. In some embodiments, the crystalline psilocybin polymorph A' described herein contains at least 15 peaks (±0.1 °2θ) of Table 2, but is absent or substantially absent of a peak at 17.5 °2θ ±0.1 °2θ. In some embodiments, the crystalline psilocybin polymorph A' described herein contains at least 20 peaks (±0.1 °2θ) of Table 2, but is absent or substantially absent of a peak at 17.5 °2θ ±0.1 °2θ. In some embodiments, the crystalline psilocybin polymorph A' described herein contains at least 25 of the peaks in Table 2 (±0.1 degrees 2θ), but is absent or substantially absent of a peak at 17.5 degrees 2θ ±0.1 degrees 2θ.

[0049] [Table 2]

[0050] In one embodiment, the crystalline psilocybin polymorph A' is characterized by XRPD diffractogram peaks at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ, but substantially absent a peak at 17.5 °2θ ± 0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph A' is further characterized by at least one additional peak occurring at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph A' is further characterized by at least two additional peaks occurring at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph A' is further characterized by the presence of a peak occurring at 10.1 °2θ ± 0.1 °2θ. It is further characterized and distinct from polymorph A. In a further embodiment, crystalline psilocybin polymorph A' exhibits an XRPD diffractogram substantially identical to the XRPD diffractogram shown in Figure 7b.

[0051] In one embodiment, the crystalline psilocybin polymorph A' is characterized by XRPD diffractogram peaks at 14.5 and 17.5°2θ±0.1°2θ, wherein the intensity of the peak at 17.5°2θ is less than 5%, such as less than 4%, such as less than 3%, such as less than 2%, such as less than 1%, or such as about 1% of the intensity of the peak at 14.5°2θ.

[0052] In one embodiment, crystalline psilocybin polymorph A' is characterized by XRPD diffractogram peaks at 10.1 and 14.5°2θ±0.1°2θ, where the intensity of the peak at 10.1°2θ is at least 1%, such as at least 2%, such as at least 3%, or such as about 4% of the intensity of the peak at 14.5°2θ.

[0053] In one embodiment, the crystalline psilocybin polymorph A' is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C. In another embodiment, the crystalline psilocybin polymorph A' is further characterized by an endothermic event in the DSC thermogram having an onset temperature of 145-165° C., such as 145-160° C., or such as 145-155° C. In another embodiment, the crystalline psilocybin polymorph A' is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C., and an endothermic event in the DSC thermogram having an onset temperature of 145-165° C., such as 145-160° C., or such as 145-155° C. In yet another embodiment, crystalline psilocybin polymorph A' exhibits a DSC thermogram substantially identical to the DSC thermogram of Figure 8b.

[0054] In another embodiment, the crystalline psilocybin polymorph A' is characterized by having a water content of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, or such as less than 0.1% w / w. Those skilled in the art will know methods for measuring the water content of a compound, such as Karl Fischer titration. In one embodiment, the crystalline psilocybin polymorph A' is characterized by having a loss of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, such as less than 0.1% w / w, in a TGA thermogram at ambient temperature, such as 25°C to 200°C. In one embodiment, the crystalline psilocybin polymorph A' loses less than 2% by weight, such as less than 1% by weight, such as less than 0.5% by weight, in a loss on drying test. The loss on drying test is performed at 70°C.

[0055] In one embodiment, the crystalline psilocybin polymorph A' is a highly pure crystalline form of polymorph A', e.g., the psilocybin comprises at least 90% by weight, such as 95% by weight, such as 99% by weight, e.g., 99.5% by weight of polymorph A'.

[0056] In one embodiment, crystalline psilocybin polymorph A' is a white to off-white solid.

[0057] In another embodiment, the crystalline psilocybin polymorph A' is chemically pure, e.g., the psilocybin has a chemical purity of greater than 97%, more preferably greater than 98%, and most preferably greater than 99% by HPLC. 31 In one embodiment, the crystalline psilocybin polymorph A' has no single impurity greater than 1%, more preferably less than 0.5%, including phosphate as measured by P NMR and psilocin as measured by HPLC. %. In one embodiment, crystalline psilocybin polymorph A' has a chemical purity of greater than 97 area%, more preferably greater than 98 area%, and most preferably greater than 99 area%. In one embodiment, crystalline psilocybin polymorph A' has no single impurity of greater than 1 area%, more preferably less than 0.5 area%, as measured by HPLC. In one embodiment, crystalline psilocybin polymorph A' does not contain psilocin at a level of greater than 1 area%, more preferably less than 0.5 area%, as measured by HPLC. In one embodiment, crystalline psilocybin polymorph A' has a chemical purity of greater than 97 area%, more preferably greater than 98 area%, and most preferably greater than 99 area%. In one embodiment, crystalline psilocybin polymorph A' has a chemical purity of greater than 97 area%, more preferably greater than 98 area%, and most preferably greater than 9 ...%. In one embodiment, crystalline psilocybin polymorph A' has a chemical purity of greater than 97 area%, more preferably greater than 98 area%, and most preferably greater than 99 area%. In one embodiment, crystalline psilocybin polymorph A' has a chemical purity of greater than 97 area%, more preferably greater than 98 area%, and most preferably greater than 99 area%. 31 It does not contain phosphate at a level of greater than 1% by weight, more preferably less than 0.5% by weight, as measured by P NMR. In one embodiment, the crystalline psilocybin polymorph A' has a chemical assay of at least 95% by weight, such as at least 96% by weight, or such as at least 98% by weight.

[0058] XRPD diffractograms and XRPD peak positions are obtained using Cu Kα radiation.

[0059] DSC and TGA thermograms are acquired using a heating rate of 20° C. / min.

[0060] In one embodiment, there is provided high purity crystalline psilocybin, polymorph A or polymorph A' (12A or 12A'), or a mixture thereof, exhibiting an XRPD diffractogram substantially as depicted in Figure 7a or Figure 7b and a DSC thermograph substantially as depicted in Figure 8a or Figure 8b.

[0061] Preferably, crystalline psilocybin polymorph A (12A) exhibits the XRPD diffractogram depicted in FIG. 7a and the DSC thermogram depicted in FIG. 8a.

[0062] Preferably, crystalline psilocybin polymorph A' (12A') exhibits an XRPD diffractogram substantially as depicted in Figure 7b and a DSC thermogram substantially as depicted in Figure 8b.

[0063] Preferably, the high purity crystalline psilocybin polymorph A (12A) is characterized by an XRPD diffractogram substantially as depicted in Figure 7a and a DSC thermograph substantially as depicted in Figure 8a.

[0064] Preferably, the high purity crystalline psilocybin polymorph A (12A') is characterized by the XRPD diffractogram shown in Figure 7b and the DSC thermogram shown in Figure 8b.

[0065] Polymorph A (including its isomorphic variant polymorph A') (Figures 7a and 7b) is distinct from polymorph B (Figure 7c), hydrate A (Figure 7d) and the ethanol solvate (Figure 7e: solvate A), and the relationships between some of these different forms are illustrated in Figure 9.

[0066] The crystalline psilocybin polymorph A or polymorph A' is a white to off-white solid and / or has a chemical purity by HPLC of greater than 97%, more preferably greater than 98%, and most preferably greater than 99%; and 31In one embodiment, high purity crystalline psilocybin, polymorph A or polymorph A' is provided. In one embodiment, the crystalline psilocybin polymorph A or polymorph A' has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % by HPLC. In one embodiment, the crystalline psilocybin polymorph A or polymorph A' has no single impurity greater than 1 area %, more preferably less than 0.5 area %, as measured by HPLC. In an embodiment, the crystalline psilocybin polymorph A or polymorph A' does not contain psilocin at a level greater than 1 area %, more preferably less than 0.5 area %, as measured by HPLC. In one embodiment, the crystalline psilocybin polymorph A or polymorph A' is 31 It does not contain phosphate at a level of greater than 1% by weight, more preferably less than 0.5% by weight, as measured by P NMR. In one embodiment, the crystalline psilocybin polymorph A or polymorph A' has a chemical assay of at least 95% by weight, such as at least 96% by weight, or such as at least 98% by weight.

[0067] Heating of polymorph A or A' results in an endothermic event with an onset temperature of approximately 150° C., corresponding to the solid-solid transition of polymorph A or A' to polymorph B. Continued heating of the resulting solid, i.e., polymorph B, results in a second endothermic event corresponding to the melting point with an onset temperature of 205-220° C. (see FIG. 8a and FIG. 8b).

[0068] In accordance with another independent aspect of the present invention, there is provided a crystalline form of psilocybin, Hydrate A, characterized by one or more of the following: a. Peaks in an XRPD diffractogram at 8.9, 12.6, and 13.8°2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 8.9, 12.6, and 13.8 °2θ ± 0.1 °2θ (further characterized by at least one additional peak at 6.5, 12.2, 19.4, 20.4, or 20.8 °2θ ± 0.1 °2θ); c. An XRPD diffractogram substantially as depicted in Figure 7d; or d. An endothermic event in a DSC thermogram with an onset temperature of 205-220° C., substantially as illustrated in FIG. 8d.

[0069] In one embodiment, psilocybin hydrate A exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 3. In one embodiment, crystalline psilocybin hydrate A described herein comprises at least three peaks in Table 3 (±0.1° 2θ). In some embodiments, crystalline psilocybin hydrate A described herein comprises at least four peaks in Table 3 (±0.1° 2θ). In some embodiments, crystalline psilocybin hydrate A described herein comprises at least five peaks in Table 3 (±0.1° 2θ). In some embodiments, crystalline psilocybin hydrate A described herein comprises at least eight peaks in Table 3 (±0.1° 2θ). In some embodiments, crystalline psilocybin hydrate A described herein comprises at least ten peaks in Table 3 (±0.1° 2θ). [Table 3]

[0070] In one embodiment, crystalline psilocybin hydrate A is characterized by XRPD diffractogram peaks at 8.9, 12.6, and 13.8 °2θ±0.1 °2θ. In another embodiment, crystalline psilocybin hydrate A is further characterized by at least one peak occurring at 6.5, 12.2, 19.4, 20.4, or 20.8 °2θ±0.1 °2θ. In another embodiment, crystalline psilocybin hydrate A is further characterized by at least two peaks occurring at 6.5, 12.2, 19.4, 20.4, or 20.8 °2θ±0.1 °2θ. In a further embodiment, crystalline psilocybin hydrate A exhibits an XRPD diffractogram substantially identical to the XRPD diffractogram shown in FIG. 7d.

[0071] In one embodiment, crystalline psilocybin hydrate A is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C. In another embodiment, crystalline psilocybin hydrate A is further characterized by an endothermic event in the DSC thermogram having an onset temperature of 85-105° C., or such as 90-100° C. In another embodiment, crystalline psilocybin hydrate A is characterized by an endothermic event in the DSC thermogram having an onset temperature of 205-220° C., such as 210-220° C., such as 210-218° C., or such as 210-216° C. and an endothermic event having an onset temperature of between 85° C. and 105° C., or between 90° C. and 100° C., etc. In yet another embodiment, crystalline psilocybin hydrate A exhibits a DSC thermogram substantially identical to the DSC thermogram of FIG. 8d.

[0072] In another embodiment, the crystalline psilocybin hydrate A is characterized by having a water content of 10-18%, such as 12-16%, or such as about 13%. Those skilled in the art will know methods for measuring the water content of a compound, such as Karl Fischer titration. In one embodiment, the crystalline psilocybin hydrate A is characterized by having a weight loss in a TGA thermogram of 10-18%, such as 12-16%, or such as about 13%, at ambient temperature to 120°C, such as about 25°C.

[0073] In one embodiment, the crystalline psilocybin hydrate A is a highly pure crystalline form of hydrate A, e.g., the psilocybin comprises at least 90% by weight, such as 95% by weight, such as 99% by weight, e.g., 99.5% by weight of hydrate A.

[0074] In accordance with another independent aspect of the present invention, there is provided a crystalline form of psilocybin, polymorph B, characterized by one or more of the following: a. peaks in an XRPD diffractogram at 11.1, 11.8, and 14.3°2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 11.1, 11.8, and 14.3 °2θ ± 0.1 °2θ (further characterized by at least one additional peak at 14.9, 15.4, 19.3, 20.0, or 20.6 °2θ ± 0.1 °2θ); c. An XRPD diffractogram substantially as depicted in Figure 7c; or d. An endothermic event in a DSC thermogram with an onset temperature of 205-220° C., substantially as illustrated in FIG. 8c.

[0075] In one embodiment, psilocybin polymorph B exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 4. In one embodiment, the crystalline psilocybin polymorph B described herein comprises at least three peaks (±0.1° 2θ) of Table 4. In some embodiments, the crystalline psilocybin polymorph B described herein comprises at least four peaks (±0.1° 2θ) of Table 4. In some embodiments, the crystalline psilocybin polymorph B described herein comprises at least five peaks (±0.1° 2θ) of Table 4. In some embodiments, the crystalline psilocybin polymorph B described herein comprises at least eight peaks (±0.1° 2θ) of Table 4. In some embodiments, the crystalline psilocybin polymorph B described herein comprises at least ten peaks (±0.1° 2θ) of Table 4. [Table 4]

[0076] In one embodiment, the crystalline psilocybin polymorph B is characterized by XRPD diffractogram peaks at 11.1, 11.8, and 14.3 °2θ±0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph B is further characterized by at least one peak occurring at 14.9, 15.4, 19.3, 20.0, or 20.6 °2θ±0.1 °2θ. In another embodiment, the crystalline psilocybin polymorph B is further characterized by at least two peaks occurring at 14.9, 15.4, 19.3, 20.0, or 20.6 °2θ±0.1 °2θ. In a further embodiment, the crystalline psilocybin polymorph B exhibits an XRPD diffractogram substantially identical to the XRPD diffractogram depicted in FIG. 7c.

[0077] In one embodiment, the crystalline psilocybin polymorph B is characterized by an endothermic event in a DSC thermogram having an onset temperature between 205 and 220° C., such as between 210 and 220° C., such as between 210 and 218° C., or such as between 210 and 216° C. In yet another embodiment, the crystalline psilocybin polymorph B exhibits a DSC thermogram substantially identical to the DSC thermogram of Figure 8c.

[0078] In another embodiment, the crystalline psilocybin polymorph B is characterized by having a water content of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, or such as less than 0.1% w / w. Those skilled in the art will know methods for measuring the water content of a compound, such as Karl Fischer titration. In an embodiment, the crystalline psilocybin polymorph B is characterized by having a loss of less than 0.5% w / w, such as less than 0.4% w / w, such as less than 0.3% w / w, such as less than 0.2% w / w, such as less than 0.1% w / w in a TGA thermogram at ambient temperature to 200° C., such as about 25° C. In one embodiment, the crystalline psilocybin polymorph B loses less than 2% by weight, such as less than 1% by weight, such as less than 0.5% by weight in a loss on drying test. The loss on drying test is performed at 70° C.

[0079] In one embodiment, the crystalline psilocybin polymorph B is a highly pure crystalline form of polymorph B, e.g., the psilocybin comprises at least 90% by weight, such as 95% by weight, such as 99% by weight, for example 99.5% by weight of polymorph B.

[0080] In another embodiment, the crystalline psilocybin polymorph B is chemically pure, e.g., the psilocybin has a chemical purity of greater than 97%, e.g., greater than 98%, or e.g., greater than 99%, by HPLC. In one embodiment, the crystalline psilocybin polymorph B is 31In one embodiment, crystalline psilocybin polymorph B has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % by HPLC. In one embodiment, crystalline psilocybin polymorph B has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % by HPLC. In one embodiment, crystalline psilocybin polymorph B has a chemical purity of greater than 1 area %, more preferably less than 0.5 area %, by HPLC. In one embodiment, crystalline psilocybin polymorph B does not contain psilocin at a level of greater than 1 area %, more preferably less than 0.5 area %, by HPLC. In one embodiment, crystalline psilocybin polymorph B has a chemical purity of greater than 97 area %, more preferably greater than 98 area %, and most preferably greater than 99 area % ... 31 It does not contain phosphate at a level of greater than 1% by weight, more preferably less than 0.5% by weight, as measured by P NMR. In one embodiment, the crystalline psilocybin polymorph B has a chemical assay of at least 95% by weight, such as at least 96% by weight, or such as at least 98% by weight.

[0081] Psilocybin of the present invention in the form of polymorph A or A' has the general properties shown in Table 5 below. [Table 5]

[0082] Psilocybin matches the spectrum set forth in Table 6 below and illustrated in the spectra of Figures 10-13. [Table 6]

[0083] High purity is achieved by careful control of reaction conditions to ensure that potential organic impurities are significantly reduced.

[0084] Known and potential impurities in psilocybin are shown in Table 7 below. [Table 7-1] [Table 7-2]

[0085] Similarly, careful handling ensures that solvent levels are always below those noted in Table 8. [Table 8]

[0086] Through careful selection of engineering methodology, the psilocybin drug substance of the present invention meets the acceptance criteria set forth in Table 9 below. [Table 9] Abbreviations used in the table: NMT = less than or equal to, NLT = greater than or equal to.

[0087] The methodology used to confirm purity is described in the detailed description.

[0088] In fact, criteria 6 to 13 are in fact fully met, as shown in Table 10 below. [Table 10] Abbreviations used in the table: NMT = less than or equal to, LT = less than.

[0089] Thus, crystalline psilocybin in the form of polymorph A or polymorph A' has a proton ( 1 H) and carbon ( 13 C) NMR, FT-infrared spectroscopy (FT-IR) and mass spectrometry (MS) - with spectra consistent with Figures 10-13.

[0090] Crystalline psilocybin in the form of polymorph A or polymorph A' meets either of the criteria set forth in Table 9 or Table 10.

[0091] According to a second aspect of the present invention, a batch of crystalline psilocybin is provided in the form of polymorph A or polymorph A' according to the first aspect of the present invention. In one embodiment, a batch of crystalline psilocybin, polymorph A or polymorph A' is provided comprising at least 10 g, more preferably at least 100 g, most preferably at least 250 g. In one embodiment, a batch of crystalline psilocybin, polymorph A or polymorph A' is provided comprising at least 10 g, more preferably at least 100 g, most preferably at least 250 g. In one embodiment, a batch of highly purified psilocybin is provided comprising at least 10 g, more preferably at least 100 g, most preferably at least 250 g. In one embodiment, a batch of highly purified psilocybin polymorph A is provided comprising at least 10 g, more preferably at least 100 g, most preferably at least 250 g. In one embodiment, a batch of highly purified psilocybin polymorph A' is provided comprising at least 10 g, more preferably at least 100 g, most preferably at least 250 g.

[0092] Alternatively, independently, the crystalline psilocybin may be in the form of hydrate A or polymorph B.

[0093] According to a third aspect of the present invention, there is provided a pharmaceutical formulation comprising crystalline psilocybin and one or more excipients.

[0094] In one embodiment, a pharmaceutical formulation is provided that includes high purity psilocybin and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes crystalline psilocybin polymorph A and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes crystalline psilocybin polymorph A' and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes high purity crystalline psilocybin, polymorph A or polymorph A' and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes high purity crystalline psilocybin polymorph A and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes high purity crystalline psilocybin polymorph A and one or more additives. In another embodiment, a pharmaceutical formulation is provided that includes high purity crystalline psilocybin polymorph A' and one or more additives.

[0095] Alternatively, independently, the crystalline psilocybin in the formulation may be in the form of hydrate A or polymorph B.

[0096] Preferred pharmaceutical excipients for oral formulations include diluents such as microcrystalline cellulose, starch, mannitol, calcium hydrogen phosphate anhydrous, or co-mixtures of silicon dioxide, calcium carbonate, microcrystalline cellulose and talc; disintegrants such as sodium starch glycolate or croscarmellose sodium; binders such as povidone, copovidone or hydroxylpropylcellulose; lubricants such as magnesium stearate or sodium stearyl fumarate; glidants such as colloidal silicon dioxide; and film coats such as Opadry II White or PVA-based Opadry II Brown.

[0097] Psilocybin is a difficult active substance to formulate for a number of reasons: first, it has poor flow properties, and second, it is used in relatively low doses, and this combination makes it difficult to ensure content uniformity upon tableting.

[0098] A good blend will have an AV, Acceptance Value, of less than 15, more preferably less than 10.

[0099] A good blend will also have a % Label claim of greater than 90%, more preferably greater than 94%.

[0100] Between them, these parameters indicate consistent dosing of psilocybin from tablet to tablet.

[0101] For many pharmaceutical tablets, standard excipients, particularly fillers, can be used. However, in formulating psilocybin tablets, applicants have found that non-standard fillers are preferred to achieve a satisfactory product.

[0102] In this regard, a functional filler was selected. The functional filler was a silicified filler, preferably silicified microcrystalline cellulose. The preferred form includes a highly compressible grade having a particle size range of about 45 to 150 microns.

[0103] Indeed, a mixture of two functional bulking agents having different particle size ranges may be used with a weight percentage favoring the larger size particles of the two.

[0104] In one embodiment, the silicified microcrystalline filler may comprise, by weight, a first filler having a particle size range of about 45-80 microns in an amount of up to 30%, more preferably up to 20%, more preferably up to 15% or less, and a second filler having a particle size range of about 90-150 microns in an amount of up to 70%, more preferably up to 80, more preferably up to 85% or more.

[0105] The formulation may further comprise or consist of a disintegrant, preferably sodium starch glycolate, a glidant, preferably colloidal silicon dioxide, and a lubricant, preferably sodium stearyl fumarate.

[0106] Further details of formulation development are provided in Example 12.

[0107] It should be noted that the formulations may contain any form of psilocybin, not just the preferred polymorphic forms disclosed.

[0108] Studerus et al. (2011) J Psychopharmacol 25(11)1434-1452 classified oral doses of psilocybin as follows: very low dose at 0.045 mg.kg, low dose at 0.115-0.125 mg / kg, medium dose at 0.115-0.260 mg / kg and high dose at 0.315 mg / kg.

[0109] Psilocybin will typically be present in a formulated dose in an amount of 0.01 mg / kg to 1 mg / kg. A typical human dose (for an adult weighing 60-80 kg) would equate to a dose of anywhere from 0.60 mg to 80 mg. In one embodiment, 2-50 mg of crystalline psilocybin, most preferably polymorph A or polymorph A', is present in a formulated dose of 2-40 mg, such as 2-10 mg, such as 5 mg, such as 5-30 mg, such as 5-15 mg, such as 10 mg, such as 20-30 mg, or such as 25 mg. In one embodiment, 2-50 mg of crystalline psilocybin, particularly polymorph A ... 50 mg of crystalline psilocybin, particularly polymorph A', is present in a dispensed dose of, such as 2-40 mg, such as 2-10 mg, such as 5 mg, such as 5-30 mg, such as 5-15 mg, such as 10 mg, such as 20-30 mg, or such as 25 mg.

[0110] A preferred adult oral dose is likely to be in the range of 1 mg to 40 mg, preferably 2 to 30 mg, more preferably 15 to 30 mg, for example 5 mg, 10 mg or 25 mg. Microdosing, typically about 1 / 10 of these doses, is also possible, with microdose formulations typically being in the range of 0.05 mg to 2.5 mg.

[0111] Preferred pharmaceutical formulations are oral dosage forms.

[0112] The oral dosage form may be a tablet or a capsule.

[0113] For tablets, it is necessary to be able to precisely disperse the active substance, which is difficult due to the low dosage and the hygroscopic and sticky nature of the active substance, which limits its flowability.

[0114] The psilocybin will be present together with one or more excipients. Preferred excipients include microcrystalline cellulose and starch, more preferably silicified microcrystalline cellulose.

[0115] According to a fourth aspect of the invention, there is provided crystalline psilocybin in the form of polymorph A or polymorph A' according to the first aspect of the invention for use in medicine. In one embodiment, crystalline psilocybin polymorph A is provided for use in medicine. In one embodiment, crystalline psilocybin polymorph A' is provided for use in medicine. In one embodiment, high purity crystalline psilocybin polymorph A is provided for use in medicine. In one embodiment, high purity crystalline psilocybin polymorph A' is provided for use in medicine.

[0116] Alternatively, independently, the crystalline psilocybin may be in the form of hydrate A or polymorph B.

[0117] According to a fifth aspect of the present invention there is provided crystalline psilocybin in the form of polymorph A or polymorph A' of the first aspect of the present invention for use in treating a central nervous system disorder.

[0118] Alternatively, independently, the crystalline psilocybin may be in the form of hydrate A or polymorph B.

[0119] In one embodiment, crystalline psilocybin, polymorph A or polymorph A' is provided for use in treating depression. In one embodiment, crystalline psilocybin, polymorph A or polymorph A' is provided for use in treating drug-resistant depression. In one embodiment, crystalline psilocybin polymorph A is provided for use in treating drug-resistant depression. In one embodiment, crystalline psilocybin polymorph A' is provided for use in treating drug-resistant depression. In one embodiment, high purity crystalline psilocybin polymorph A is provided for use in treating drug-resistant depression. In one embodiment, high purity crystalline psilocybin polymorph A' is provided for use in treating drug-resistant depression.

[0120] Other conditions that may be treated include anxiety disorders, including anxiety in advanced stages of illness, e.g. cancer, and generalized anxiety disorder, depression, including major depressive disorder, cluster headaches, obsessive-compulsive disorder, personality disorders, including conduct disorder, drug disorders, including alcoholism, nicotineism, opioidism, cocaineism, and other addictions, including gambling addiction, eating disorders, and body dysmorphic disorder. A further condition is the treatment of pain.

[0121] According to a sixth aspect of the present invention there is provided a method of treating a central nervous system disorder comprising administering to a subject in need thereof an effective dose of crystalline psilocybin in the form of polymorph A or polymorph A' according to the first aspect of the invention.

[0122] In one embodiment, a method of treating depression is provided comprising administering an effective dose of crystalline psilocybin in the form of polymorph A or polymorph A' to a subject in need of such treatment. In one embodiment, a method of treating drug-resistant depression is provided comprising administering an effective dose of crystalline psilocybin in the form of polymorph A or polymorph A' to a subject in need of such treatment. In one embodiment, a method of treating drug-resistant depression is provided comprising administering an effective dose of psilocybin polymorph A to a subject in need of such treatment. In one embodiment, a method of treating drug-resistant depression is provided comprising administering an effective dose of psilocybin polymorph A' to a subject in need of such treatment. In one embodiment, a method of treating drug-resistant depression is provided comprising administering an effective dose of high purity crystalline psilocybin polymorph A to a subject in need of such treatment. In one embodiment, a method of treating drug-resistant depression is provided, comprising administering to a subject in need thereof an effective dose of high-purity crystalline psilocybin polymorph A'.

[0123] Alternatively, independently, the crystalline psilocybin may be in the form of hydrate A or polymorph B.

[0124] To produce the psilocybin of the present invention, psilocybin was crystallized from water in a controlled manner.

[0125] According to a seventh aspect of the present invention, there is provided a method for the large scale manufacture of psilocybin, characterised in that the method comprises subjecting psilocybin to a water crystallisation step together with controlled drying to produce crystalline psilocybin polymorph A according to the first aspect of the present invention.

[0126] In one embodiment, a method is provided for the large scale production of psilocybin, the method comprising subjecting psilocybin to a water crystallization step with controlled drying to produce crystalline psilocybin polymorph A having the XRPD diffractogram illustrated in Figure 7a and the DSC and TGA thermographs illustrated in Figure 8a. In one embodiment, a method is provided for the large scale production of psilocybin, the method comprising subjecting psilocybin to a water crystallization step with controlled drying to produce high purity crystalline psilocybin-polymorph A having the XRPD diffractogram illustrated in Figure 7a and the DSC thermograph illustrated in Figure 8a.

[0127] Preferably, polymorph A is an isomorphic variant having the XRPD diffractogram depicted in Figure 7a and the DSC thermogram depicted in Figure 8a.

[0128] More preferably, psilocybin is recrystallized, typically in about 10-20 volumes of water, heated with stirring to a temperature of at least 70°C, polished filtered to an appropriate cutoff (typically less than 5 μm), seeded at a temperature of about 70°C, and cooled in a controlled manner to about 5°C over a period of greater than 2 hours.

[0129] More preferably, the method includes controlled cooling to reduce the temperature by about 5° C. to 15° C. per hour, more preferably about 10° C. per hour.

[0130] Preferably, the polishing filtration step is carried out through a suitably sized filter, such as a 1.2 μm in-line filter.

[0131] Preferably, the stirring is at about 400 to 500 rpm, typically at about 450 rpm.

[0132] Preferably, the crystalline seed is psilocybin hydrate A. In one embodiment, 0.1% by weight or less of the crystalline seed is added to the process.

[0133] Preferably, the crystalline psilocybin is isolated by vacuum filtration.

[0134] In one embodiment, the isolated crystals are dried in vacuum at a temperature of at least 30°C, for example 30-50°C, or for example 40-50°C. In one embodiment, the isolated crystals are dried in vacuum for at least 10 hours, for example 12-18 hours, or for example about 30 hours. In one embodiment, the isolated crystals are dried in vacuum at a temperature of at least 30°C, for example 30-50°C, or for example 40-50°C, for at least 10 hours, for example 12-18 hours, or for example about 30 hours. In one embodiment, the isolated crystals are dried until the isolated crystals lose less than 2% of their weight, for example less than 0.5% of their weight in a loss on drying test.

[0135] Preferably, the isolated crystals are washed several times in water and dried in vacuum at about 50° C. for at least 12 hours.

[0136] The resulting crystals are typically relatively large (in the range of 50-200 microns) and uniform when viewed under a 10x microscope, as illustrated in Figure 16a.

[0137] This differs from the crystals obtained without controlled cooling, which are much smaller in size (typically 5-50 microns) when viewed under a 10x microscope, as illustrated in Figure 16b.

[0138] According to an eighth aspect of the present invention there is provided psilocybin according to the first aspect of the present invention obtained by the crystallization method of the present invention.

[0139] According to a ninth aspect of the present invention there is provided a pharmaceutical formulation comprising psilocybin according to the first aspect of the present invention obtained by the crystallization method of the present invention.

[0140] The psilocybin produced prior to crystallization may be produced using any method, synthetic or biological, for example by fermentation or obtained by extraction from mushrooms.

[0141] A preferred method of preparation uses psilocin or 4 hydroxy-indole as the starting material.

[0142] According to a tenth aspect of the present invention, there is provided a method for the large scale production of psilocybin from psilocin, comprising the steps of: i) Stage 4 - Reacting psilocin with tetrabenzyl pyrophosphate to form benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate; and ii) Stage 5 – Reacting benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate with hydrogen to form psilocybin.

[0143] According to an eleventh aspect of the present invention, there is provided a process for the large scale production of psilocybin from 4-hydroxyindole comprising the steps of: i) Stage 1 - Reacting 4-hydroxyindole with acetic anhydride to form 1H-indol-4-yl acetate; ii) Stage 2 - reacting 1H-indol-4-yl acetate with oxalyl chloride and dimethylamine to form 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4yl-acetate; iii) stage 3 - reacting 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate with lithium aluminum hydride to form psilocin; iv) Stage 4 - reacting psilocin with tetrabenzyl pyrophosphate to form benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate; and v) Stage 5 – Reacting benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate with hydrogen to form psilocybin.

[0144] According to a twelfth aspect of the present invention, there is provided a method for large scale production of psilocybin according to the tenth or eleventh aspects of the present invention, further comprising: vi) Stage 6 - A water crystallization step, accompanied by controlled drying, to produce crystalline psilocybin polymorph A according to the first embodiment of the present invention.

[0145] In one embodiment, there is provided a method for large scale production of psilocybin according to the tenth or eleventh aspect of the invention, further comprising: vi) Stage 6 - A water crystallization step, followed by controlled drying, to produce crystalline psilocybin polymorph A having an XRPD diffractogram substantially as depicted in Figure 7a and a DSC thermograph substantially as depicted in Figure 8a.

[0146] In one embodiment, there is provided a method for large scale production of psilocybin according to the tenth or eleventh aspect of the invention, further comprising: vi) Stage 6 - Aqueous crystallization step, accompanied by controlled drying, to produce high purity crystalline psilocybin-polymorph A having the XRPD diffractogram depicted in Figure 7a and the DSC thermogram depicted in Figure 8a.

[0147] Preferably, the crystalline psilocybin is polymorph A.

[0148] In developing a methodology for the large scale production of psilocin or psilocybin, Applicant has overcome one or more significant problems in each of Stages 1-5, and these problems are considered in the context of each step in the large scale production of psilocin or psilocybin, and more precisely, the process in which each problem is overcome is considered a separate and independent invention since it has use in the manufacture of other active substances, be they other derivatives, salts, esters, etc. that provide intermediates or prodrugs to psilocin, psilocybin, etc.

[0149] Preferably, the Stage 4(i) reaction involves the use of sodium hexamethyldisilazane (NaHMDS).

[0150] This has the advantage over the use of butyllithium in that i) it is easier to handle and ii) it does not introduce lithium into the reaction which would cause problems in downstream processing.

[0151] Preferably, the reaction uses the solvent THF.

[0152] This has the advantage that the product obtained is obtained with a significantly higher purity.

[0153] Preferably, in (i), the reaction is initiated below -50°C.

[0154] This has the advantage of reducing the level of an impurity (m / z 295.2 as observed by LCMS) that can subsequently affect purity downstream.

[0155] More preferably, the process stage 4(ii) uses THF as the solvent.

[0156] This has the advantage of ensuring that thickening is avoided and facilitates a simple stir out process to obtain the product.

[0157] Preferably, process stage 4(ii) comprises an agitation process to obtain benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate.

[0158] The stirring process has the advantages of simplifying the process and improving the yield.

[0159] The level of intermediate 4A is monitored to ensure that the Stage 4(ii) reaction is run to completion, and once complete, benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate is filtered and oven dried.

[0160] This has the advantage that impurities are minimised and a purer product is obtained.

[0161] Preferably, the Stage 5 reaction is monitored for the level of intermediates by HPLC using relative retention time (RRT) and completion is determined when the intermediate is present at less than 0.2%.

[0162] The psilocybin crude (Stage 5 product, (12)) has the major Stage 5 impurities, whose relative retention times (RRT) in the HPLC method are about 1.89 and 2.45, respectively, as well as psilocin (RRT 1.66). These impurities are listed in Table 7. Typically, the psilocybin crude (Stage 5 product (12)) has 0.24 area % of the RRT 1.89 impurity, 0.03 area % of the RRT 2.45 impurity, and 1.86 area % of psilocin. In addition, the pyrophosphate impurity (RRT 0.31) is present in the psilocybin crude at a level of, for example, about 2-6 area % by HPLC.

[0163] At this level, a subsequent crystallization process can be carried out to provide substantially pure psilocybin, e.g., psilocybin having a purity of at least 95 area %, such as at least 98 area %, or such as at least 99 area % by HPLC. In one embodiment, the pyrophosphate impurity (RRT0.31) is present in the substantially pure psilocybin at a level of less than 0.3 area %, such as less than 0.2 area %, or such as less than 0.1 area %, by HPLC.

[0164] Additionally, water is added to the reaction during this stage to keep the psilocybin in solution.

[0165] Preferably, the catalyst is recovered by filtration.

[0166] Preferably, in stage 1, the reaction is carried out in DCM and pyridine.

[0167] This has the advantage that flammable solvents are avoided.

[0168] Preferably, the reaction mixture is washed with citric acid to provide a pH of about 2-3 and to remove excess pyridine, and the acid phase is separated from the DCM phase.

[0169] This has the advantage that intermediate 2A can be isolated and purified free of excess oxalyl chloride.

[0170] More preferably, the DCM phase is further washed with sodium bicarbonate at about pH 8.

[0171] This has the advantage of a purer process.

[0172] Preferably, 1H-indol-4-yl acetate is precipitated in heptane.

[0173] This aids in precipitation and overcomes the problem of partial solubility.

[0174] Preferably, magnesium sulfate is used as the drying agent.

[0175] Preferably, the solvents tert-butyl methyl ether (TBME) and tetrahydrofuran (THF) are used.

[0176] Preferably, the reaction with oxalyl chloride is carried out at about 30°C to 40°C.

[0177] This has the advantage that a high reaction rate is ensured, giving an improved level of completion.

[0178] Preferably, intermediate 2A is isolated by filtration.

[0179] This has the advantage that the intermediate is purified free of excess oxalyl chloride.

[0180] Preferably, in stage 2, step i, intermediate 2A is also washed to remove excess oxalyl chloride.

[0181] Preferably, intermediate 2A is washed with TBME.

[0182] Preferably, heptane addition is performed to precipitate further intermediate 2A.

[0183] Preferably, in stage 2, step ii, dimethylamine is used in excess.

[0184] This has the advantage that further improved impurity profiles and yields are obtained.

[0185] Preferably, the pH is maintained at or above pH 7.

[0186] Preferably, the reaction is carried out in TBME.

[0187] Preferably, this stage further comprises a purification step to remove dimethylamine salts.

[0188] This has the advantage that purity is improved.

[0189] Preferably, this stage includes a slurrying and filtering step.

[0190] This has the advantage of improved handling and purity.

[0191] More preferably, this stage involves slurrying with water and / or IPA, filtering, and drying the isolated 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate.

[0192] This has the advantages of improved purity and yield, and reduced hydrolysis.

[0193] Preferably, in stage 3, the reaction is carried out in the solvent THF.

[0194] This has the advantage that a suspension / emulsion is formed without thickening.

[0195] Preferably, 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate is added to a solution of LiAlH4 in THF.

[0196] Preferably, the reaction is quenched with acetone, followed by citric acid, ensuring that the mixture remains strongly basic (pH 11 or above).

[0197] This has the advantage that a high yield is obtained.

[0198] Preferably, the psilocin is filtered, washed in THF, slurried in PrOAc:TBME, filtered, washed in TBME, and dried.

[0199] This has the advantage that a highly pure product is obtained, for example at least 95% pure by HPLC, for example at least 98% pure by HPLC, or for example at least 99% pure by HPLC.

[0200] A preferred method of production includes each of stages 1-6, although it will be understood that each of the features of each stage can exist independently or can be used in combination with any other feature from the same or different steps of the reaction.

[0201] Psilocybin in the given form, polymorph A or polymorph A', and of such high purity has not been obtained before, and to Applicant's knowledge, in particular Applicant's production of polymorph A and polymorph A' (as depicted in Figures 7a and 7b and Figures 8a and 8b), is novel. Indeed, the production of large batch quantities of polymorph A is novel. The crystallization methodology and, in part, the manufacturing process of the present invention result in the ability to obtain crystalline psilocybin of such high chemical purity.

[0202] Furthermore, given the labile nature of the compound, crystalline forms have been obtained that have been shown to be stable for at least 12 months under accelerated conditions (described below).

[0203] Polymorphs A and A' (Figures 7a and 7b) are distinct from polymorph B (Figure 7c), hydrate A (Figure 7d) and the ethanol solvate (Figure 7e) and mixture (Figure 7f (top)), as evidenced by their XRPD diffractograms and DSC thermographs, as described below. different.

[0204] The relationships between the different polymorphs are shown in FIG.

[0205] Indeed, the size and shape of the crystals are determined by the crystallization methodology, which in turn can affect the stability and ability to formulate the product.

[0206] In a particularly preferred embodiment, psilocybin is produced through a six-stage process, as outlined below.

[0207] According to another aspect of the present invention, there is provided a method for the preparation of crystalline psilocybin according to the first aspect of the present invention, characterized in that the method comprises subjecting psilocybin to a water crystallization step together with controlled drying to produce crystalline psilocybin polymorph A or polymorph A' according to the first aspect of the present invention. In one embodiment, there is provided a method for the preparation of crystalline psilocybin according to the first aspect of the present invention, characterized in that the method comprises a water crystallization step together with controlled drying to produce crystalline psilocybin-polymorph A or polymorph A' having an XRPD diffractogram substantially as illustrated in Figure 7a or Figure 7b and a DSC thermogram substantially as illustrated in Figure 8a or Figure 8b. In one embodiment, there is provided a method for the manufacture of psilocybin according to the first aspect of the present invention, characterized in that said method comprises a water crystallization step together with controlled drying to produce high purity crystalline psilocybin-polymorph A or polymorph A' having the XRPD diffractogram depicted in Figure 7a or 7b and the DSC thermogram depicted in Figure 8a or 8b.

[0208] Preferably, Polymorph A and Polymorph A' are isomorphic variants having XRPD diffractograms substantially as depicted in Figures 7a and 7b and DSC thermographs substantially as depicted in Figures 8a and 8b.

[0209] More preferably, the psilocybin is recrystallized in about 10-20 volumes of water, heated with stirring to a temperature of at least 70°C, polished filtered to an appropriate cutoff (typically less than 5 μm), seeded at a temperature of about 70°C, and cooled in a controlled manner to about 5°C over a period of greater than 2 hours.

[0210] More preferably, the method includes controlled cooling to reduce the temperature by about 5° C. to 15° C. per hour, more preferably about 10° C. per hour.

[0211] Preferably, the polishing filtration step is carried out through a suitable size filter, such as a 1.2 μm or 0.45 μm in-line filter.

[0212] Preferably, the stirring is at about 400 to 500 rpm, typically at about 450 rpm.

[0213] Preferably, the crystalline seed is psilocybin hydrate A. In one embodiment, 0.1% by weight or less of the crystalline seed is added to the process.

[0214] Preferably, the crystalline psilocybin is isolated by vacuum filtration.

[0215] In one embodiment, the isolated crystals are dried in vacuum at a temperature of at least 30° C., such as 30-50° C., or such as 40-50° C. In one embodiment, the isolated crystals are dried in vacuum for at least 10 hours, such as 12-18 hours, or such as about 30 hours. In one embodiment, the isolated crystals are dried in vacuum at a temperature of at least 30° C., such as 30-50° C. or such as 40-50° C., for at least 10 hours, such as 12-18 hours or such as about 30 hours. In one embodiment, the isolated crystals are dried until they lose less than 2% weight, such as less than 0.5% weight in a loss on drying test.

[0216] Preferably, the isolated crystals are washed several times in water and dried in vacuum at about 50° C. for at least 12 hours.

[0217] The resulting crystals are typically relatively large (in the range of 50-200 microns) and uniform when viewed under a 10x microscope, as illustrated in Figure 16a.

[0218] This differs from the crystals obtained without controlled cooling, which are much smaller in size (typically 5-50 microns) when viewed under a 10x microscope, as illustrated in Figure 16b. Stage 1: Synthesis of 1H-indol-4-yl acetate (3)

[0219] The core reaction is the reaction of 4-hydroxyindole (1) with acetic anhydride (2) to form 1H-indol-4-yl acetate (3) (Figure 2).

[0220] Most preferably, stage 1 is as follows.

[0221] 4-Hydroxyindole (1), DCM (12) and pyridine (13) are added to a vessel and cooled to about 0-5 °C. Acetic anhydride (2) is added dropwise and the mixture is warmed to about 20-25 °C and stirred until complete by HPLC. The reaction mass is washed with aqueous citric acid (14) and aqueous NaHCO3 (15), dried over MgSO4 (16), filtered and evaporated to about half volume. Heptane (17) is added and distillation is continued to remove most of the DCM. The mixture is cooled to about 5-25 °C, filtered, washed with heptane and dried in a vacuum oven overnight to isolate 1H-indol-4-yl acetate (3) as a solid suitable for use in the following stage. Stage 2: Synthesis of 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate (6)

[0222] The core reaction is the reaction of 1H-indol-4-yl acetate (3) with oxalyl chloride (4) and dimethylamine (5) to form 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate (6) (Figure 3).

[0223] Most preferably, stage 2 is as follows.

[0224] 1H-Indol-4-yl acetate (3) is dissolved in a mixture of THF (19) and TBME (18) at room temperature. Oxalyl chloride (4) is added dropwise, allowing the reaction to exotherm at about 35-40° C. The temperature range is maintained throughout the remainder of the addition. The reaction is then stirred at about 40° C. until complete by HPLC. The reaction is cooled to room temperature and heptane (17) is added, precipitating additional solids. The slurry is stirred, then allowed to settle, followed by decantation to remove most of the solvent (18 / 19). The solids are washed in a vessel twice with heptane (17). TBME (18) is added to give a yellow slurry, and the mixture is cooled to about −20° C. Dimethylamine solution (5) is added, maintaining the temperature at −20° C. to −10° C. The reaction is then warmed to room temperature and stirred until complete, adding additional dimethylamine if necessary. The reaction was filtered, washed with heptane (17) and dried in a vacuum oven. Slurry in water (20) and then IPA (21). The crude 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate (6) was further purified by ethyl acetate, followed by drying in a vacuum oven to give (6) as a solid suitable for use in the next stage. Stage 3: Synthesis of 3-(2-(dimethylamino)ethyl)-1H-indol-4-ol (psilocin) (8)

[0225] The core reaction is the reaction of 3[(dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate (6) with lithium aluminum hydride (7) to form psilocin (8) (Figure 4).

[0226] Most preferably, stage 3 is as follows.

[0227] 3[(Dimethylcarbamoyl)carbonyl]-1H-indol-4-yl-acetate (6) was slurried in THF (19) and cooled to about 0 °C. A THF solution of LiAlH4 (7) was added dropwise while maintaining the temperature at about 0-20 °C. The reaction was then refluxed until complete by HPLC. The reaction was cooled to 0 °C and excess LiAlH4 was quenched by the addition of acetone (22) followed by aqueous citric acid (14). The batch was filtered to remove lithium and aluminum salts. The filtrate was dried with MgSO4 (16), filtered, concentrated, and loaded onto a silica pad (23). The pad was eluted with THF (19) and the fractions containing the product were evaporated. The resulting solid was slurried in a mixture of iPrOAc:TBME (24 / 18), filtered, and washed with TBME. The solid was dried in an oven to give high purity psilocin (8) as an off-white solid. Stage 4: Synthesis of benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate (10)

[0228] The core reaction is the reaction of psilocin (8) with tetrabenzyl pyrophosphate (9) to form benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate (10) (Figure 5).

[0229] Most preferably, stage 4 is as follows.

[0230] Psilocin (8) was added to the vessel followed by THF (19). The reaction was cooled to -50°C to -70°C and NaHMDS (25) was added dropwise at about -45°C to -70°C. The temperature was adjusted to about -45°C to -60°C and tetrabenzyl pyrophosphate in THF was added. The batch was warmed to 0°C after which the solid by-product was removed by filtration and the filtrate was concentrated in vacuo. The concentrated mixture was then heated to about 40°C and stirred until the intermediate was converted to the stage 4 product (10) as controlled by monitoring and the use of HPLC. The batch was cooled to about 0-5°C and the resulting solid was isolated by filtration and dried in vacuo to give benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate (10) as a solid. Stage 5: Synthesis of intermediate grade 3-[2-(dimethylazaniumyl)ethyl]-1H-indol-4-yl hydrogen phosphate (crude psilocybin) (12)

[0231] The core reaction involves reacting benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate (10) with hydrogen (11) to form psilocybin (12) (Figure 6).

[0232] Most preferably, stage 5 is as follows.

[0233] Pd / C (26), methanol (24) and 3-[2-(benzyldimethylazanium [1H-indol-4-yl]ethyl phosphate (10) was added to the vessel and the resulting mixture was pumped with hydrogen (11) until complete by HPLC. Purified water (20) was added during the process to keep the product in solution. The mixture was heated to about 35° C.-45° C. and then filtered through a bed of Celite (27), washing with methanol (24) and purified water (20). The filtrate was evaporated in vacuo and azeotroped with ethanol (28) to give intermediate grade psilocybin (12). Stage 6: Synthesis of 3-[2-(dimethylazaniumyl)ethyl]-1H-indol-4-yl hydrogen phosphate (psilocybin)

[0234] The core purification / polymorph determination step is a water crystallization step, followed by a controlled cooling and drying step, to produce high purity crystalline psilocybin, polymorph A or polymorph A'.

[0235] Most preferably, stage 6 is as follows.

[0236] The intermediate grade psilocybin (12) (Stage 5) was added to a vessel with purified water (20) and the mixture was heated until the psilocybin (12) was dissolved. The resulting bulk solution was then finish filtered into a pre-warmed vessel. The temperature was adjusted, preferably to about 68°C-70°C, and psilocybin hydrate crystal seed (i.e., Hydrate A) was added to the reaction. The batch was then cooled in a controlled manner to about 0-10°C, stirred, and the solids were collected by filtration and washed with purified water. The isolated solids were then dried in vacuum to obtain high purity crystalline psilocybin, polymorph A or A', as an off-white solid. [Brief description of the drawings]

[0237] In the following, embodiments of the present invention will be further described with reference to the accompanying drawings. [Figure 1] FIG. 1 is a schematic diagram of the reactions taught in JNP. [Diagram 2] FIG. 2 is a schematic diagram of the Stage 1 reaction of one embodiment of the present invention. [Diagram 3] FIG. 3 is a schematic diagram of the Stage 2 reaction of one embodiment of the present invention. [Figure 4] FIG. 4 is a schematic diagram of the Stage 3 reaction of one embodiment of the present invention. [Diagram 5] FIG. 5 is a schematic diagram of the Stage 4 reaction of one embodiment of the present invention. [Figure 6] FIG. 6 is a schematic diagram of the Stage 5 reaction of one embodiment of the present invention. [Figure 7A]FIG. 7A is an XRPD diffractogram of polymorph A (GM764B). [Figure 7B] FIG. 7B is an XRPD diffractogram of polymorph A' (JCCA2160F). [Figure 7C] FIG. 7C is an XRPD diffractogram of polymorph B (JCCA2160-F-TM2). [Figure 7D] FIG. 7D is an XRPD diffractogram of hydrate A (JCCA2157E). [Figure 7E] FIG. 7E is an XRPD diffractogram of the ethanol solvate (JCCA2158D). [Figure 7F] FIG. 7F is an XRPD diffractogram (top) of the product (CB646-E) obtained during the development of this process compared to diffractograms of polymorph A′ (JCCA2160F) (middle) and polymorph B (JCCA2160-TM2) (bottom). [Figure 8A] FIG. 8A is the DSC and TGA thermographs of polymorph A (GM764B). [Figure 8B] FIG. 8B is a DSC and TGA thermograph of polymorph A' (JCCA2160F). [Figure 8C] FIG. 8C is a DSC thermograph of polymorph B (GM748A). [Figure 8D] FIG. 8D is a DSC and TGA thermograph of Hydrate A (JCCA2157E). [Figure 8E] FIG. 8E is a DSC and TGA thermograph of the ethanol solvate (JCCA2158D). [Figure 9] FIG. 9 is a morphology phase diagram showing the interrelationships of morphologies in water-based systems. [Figure 10] FIG. 10 is a 1H NMR spectrum of psilocybin (read in conjunction with Assignment Example 7). [Figure 11] FIG. 11 is a 13C NMR spectrum of psilocybin (read in conjunction with Assignment Example 7). [Figure 12] Figure 12 is an FT-IR spectrum of psilocybin. [Figure 13] Figure 13 is a mass spectrum of psilocybin. [Figure 14] FIG. 14 is the numbered structural formula of psilocybin. [Figure 15] FIG. 15 is a temperature solubility curve for psilocybin in water. [Figure 16A] FIG. 16A is a micrograph showing crystals obtained by controlled cooling. [Figure 16B] FIG. 16B is a micrograph showing crystals obtained by uncontrolled freeze-drying. [Figure 17] FIG. 17 is a morphological phase diagram showing the interrelationship of morphologies in different solvent systems. [Figure 18] FIG. 18 is an XRPD diffractogram-Pattern C for solids isolated at 25 and 50° C. [Figure 19] FIG. 19 is the XRPD diffractogram patterns D, E and F for the solids isolated at 25 and 50° C. [Figure 20] FIG. 20 is a comparison of XRPD diffractograms obtained for solids isolated from equilibration of amorphous psilocybin in solvents A through H. [Figure 21] FIG. 21 is a comparison of XRPD diffractograms obtained for solids isolated from equilibration of amorphous psilocybin in solvents IP. [Figure 22] FIG. 22 is a comparison of XRPD diffractograms obtained for solids isolated from equilibration of amorphous psilocybin in solvents R through Y. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0238] In contrast to the prior art, the present invention aims to produce psilocybin on a commercial large scale in quantities or batches of at least 100 g, more preferably at least 250 g, levels one or two logs higher than those described in the JNP (which describes "large" scale processes for producing gram quantities on a 10 g scale). To demonstrate the many key development steps from JNP, the following description details the experiments and studies conducted at each of the process stages and illustrates the choices made to overcome the many technical challenges faced in producing GMP-compliant psilocybin (7) (including various intermediates (2-6)) on a large scale, starting from 4-hydroxyindole (1).

[0239] Reference to a particular numerical value includes at least that particular value unless the context clearly dictates to the contrary. When a range of values ​​is expressed, another embodiment includes from the one particular value and / or to the other particular value. Further, reference to values ​​expressed in ranges includes every individual value within that range. All ranges are inclusive and combinable.

[0240] When values ​​are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment.

[0241] As used herein, the singular forms "a," "an," and "the" include the plurals.

[0242] When used in reference to a numerical range, cutoff or specific value, the use of "about" The term "about" is used to indicate that the indicated value may vary from the listed value by up to 10%. Many of the numerical values ​​used herein are experimentally determined, and it should be understood by those skilled in the art that such determinations may often vary from different experiments. Due to this inherent variation, the values ​​used herein should not be considered overly limiting. Thus, the term "about" is used to encompass ±10% or less variation, ±5% or less variation, ±1% or less variation, ±0.5% or less variation, or ±0.1% or less variation from the specified value.

[0243] As used herein, "treating" and similar terms refer to reducing the severity and / or frequency of symptoms, eliminating symptoms and / or the underlying causes of said symptoms, reducing the frequency or likelihood of symptoms and / or their underlying causes, slowing, preventing and / or retarding the progression of a disease and / or disorder, and ameliorating or correcting damage caused directly or indirectly by a disease and / or disorder.

[0244] The following abbreviations are used herein: DSC - Differential Scanning Calorimetry RT-room temperature TBME-Methyl tert-butyl ether TGA-Thermogravimetric analysis THF - Tetrahydrofuran Regarding wrt- XRPD - X-ray powder diffraction EXAMPLES

[0245] [Example 1] Stage 6 Crystallization process and resulting polymorphs Experiments to produce Form A': 1.0 g of crude psilocybin was added to a 25 mL flask. Water (12.8 mL / 16 vol based on activity of input material) was added. The mixture was stirred and heated to 80° C. A dark brown solution with visible undissolved solids was obtained. The mixture was finish filtered through a warmed 0.45 μm filter into a hot 25 mL flask. Undissolved solids were removed to give a dark brown solution. The solution was re-equilibrated at 75° C. and then cooled slowly (10° C. / hr) to ambient temperature. The resulting light brown solution was allowed to equilibrate at ambient temperature for 16 hours. The suspension was cooled to 5° C. before isolation of the solids by vacuum filtration. The filter cake was washed with water (0.8 mL / 1 vol) and dried in vacuum at 50° C. for 16 hours. 75% yield, chemical purity 99%, NMR assay >98%.

[0246] The above procedure was repeated with 14 volumes (11.2 mL) of water. 69% yield, chemical purity 99%, NMR assay >98%.

[0247] In both cases, dissolution of crude psilocybin was achieved at approximately 75° C. Upon gradual cooling, precipitation was observed at approximately 60° C.

[0248] In both cases, psilocybin polymorph A' was produced and confirmed by XRPD (diffractograms consistent with FIG. 7b) and DSC (thermograms consistent with FIG. 8b). Experiments to produce Form A

[0249] The 94 g of crude psilocybin obtained from the Stage 5 process (about 93% pure by HPLC with about 4% pyrophosphate impurity) was subjected to aqueous recrystallization as described below. did.

[0250] The protocol used ample water (12 volumes), a rapid stirring rate (450 rpm) and a controlled cooling profile (10° C. / hr).

[0251] Psilocybin (94.0 g) (CB650E) was added to a 2 L flask. Water (902 ml, 12 volumes based on the activity of the input material) was added. The mixture was stirred and heated to approximately 78°C. A dark brown solution with visible undissolved solids was obtained. The mixture was finish filtered through a 1.2 μm in-line filter into a hot 5 L flask fitted with an overhead stirrer (450 rpm). Undissolved solids were removed to give a clarified dark brown solution. The solution was re-equilibrated at approximately 75°C for 15 minutes and then cooled slowly (10°C / hr) to ambient temperature. After aging in water at 68-70°C, the solution was seeded with psilocybin hydrate A (GM758A - XRPD diffractogram consistent with Figure 7d). The resulting light brown suspension was allowed to equilibrate at ambient temperature for approximately 16 hours. The suspension was cooled to 5°C for 1 hour before isolation of the solids by vacuum filtration. The filter cake was washed with water (282 mL, 3 vol) and dried in vacuum at about 50° C. for 30 hours.

[0252] The process was successfully completed with a yield of 75%. The chemical purity of the solid was determined to be 99.3%. Analysis of the solid by XRPD after drying for 30 hours showed polymorph A (Figure 7a). Characteristic perturbations were observed at approximately 17° 2θ, such as 17.5° 2θ, which was prominent in the bulk material. Solid-state characterization of polymorph A and polymorph A'

[0253] The DSC and TGA thermograms obtained for polymorph A (Figure 8a) were comparable to those obtained for polymorph A' (Figure 8b). The TGA thermograms obtained for polymorph A and polymorph A' (Figure 8a) show no weight loss prior to decomposition, suggesting that the difference between the XRPD obtained for polymorph A (Figure 7a, there is a perturbation at approximately 17° 2θ) and the XRPD obtained for polymorph A' obtained on a smaller scale (Figure 7b, there is no perturbation) is not due to excess hydration.

[0254] Solid microscopy (Figure 16a) shows rod-shaped crystals with good uniformity and in the size range between 50 and 200 microns.

[0255] The XRPD diffractogram obtained for polymorph A' does not show the same degree of perturbation at approximately 17° 2θ as polymorph A. The perturbation in the XRPD diffractogram at approximately 17° 2θ was more pronounced and unexpected for psilocybin produced on a large scale (compared to that obtained on a small scale). Applicants have demonstrated that hydrate A is the only polymorphic form that exists over a wide range of temperatures without a diffraction peak in the 17° 2θ region (see FIG. 7d). This strongly suggests that hydrate A collapses upon dehydration to give polymorphs A or A', varying with scale, and that polymorph A is the authentic form, while polymorph A' formed on a small scale is atypical.

[0256] To test the validity of this theory and to demonstrate recovery to polymorph A, a small amount of the bulk was re-dried after re-immersion in water (to regenerate hydrate A). A small sample (250 mg - psilocybin polymorph A) was equilibrated in water (10 volumes) for 1 hour. The suspension was filtered and analysis of the wet solid confirmed that hydrate A had been produced (Figure 7d) with no perturbation at 17°2-theta. This material was dried in vacuum for 16 hours and the solid was re-evaluated by XRPD. Polymorph A' material was confirmed by XRPD (Figure 7b) with a decrease in XRPD perturbation. Further drying and aging of the original bulk solid at ambient temperature did not change the XRPD diffractogram of the solid. Two solid forms were obtained, polymorph A and polymorph A. The XRPD diffractograms for polymorph A and polymorph A' are virtually identical except for the peak at approximately 17.5° 2-theta. The thermal properties are also identical. The differences between the XRPD diffractograms of polymorph A and polymorph A' are minor, and both polymorphs convert very rapidly and kinetically to the hydrated state.

[0257] Further experiments were performed to ascertain whether the differences in the XRPD diffractograms of polymorph A and polymorph A' were due to a more extensive crystallization process that subsequently gave larger particle size solids that did not dry as effectively, causing the change, or whether they were due to differences in crystal habit and size of the crystalline solids. Psilocybin polymorph A (the polymorphic form identified prior to the experiment) was ground using a mortar and pestle and evaluated by XRPD. No change in polymorph was observed. Another portion (51 mg) was added with water (<1 mL) and evaluated for moisture to confirm that a hydrate had formed. Both lots were dried in vacuum at 50° C. for approximately 18 hours and re-evaluated by XRPD. The ground sample remained as polymorph A. The hydrated sample after dehydration was shown to be polymorph A' (i.e., no reflection at approximately 17.5° 2θ). This suggested that size / crystal habit alone was not the only reason for the original reflection peaks.

[0258] TGA evaluation revealed that the input lot exhibited low mass loss (0.139% weight) by approximately 70° C. The reduced particle size and subsequently dried solid exhibited a greater mass loss of 0.343% weight by approximately 75° C., while the hydrated and dried solid exhibited the least mass loss of 0.069% weight by approximately 80° C. The reduced particle size and subsequently dried solid was held at 80° C. for 10 minutes (past the point of mass loss by TGA), yet evaluation by XRPD revealed no change from the input, implying that low levels of hydration and partial swelling of the crystal lattice were not the cause of variation.

[0259] It is possible to produce polymorph A' via hydration of polymorph A and subsequent drying of the isolated solid on a small scale.

[0260] Approximately 60 mg of psilocybin polymorph A and polymorph A' were each added with 0.2 ml of water to give hydrate A from both lots. Half of each hydrate A was dried in vacuum at 25° C. for approximately 17 1 / 4 hours, and the remaining portion of each hydrate A was dried under a N2 stream at ambient temperature for approximately 17 1 / 4 hours. Solids were isolated after drying and evaluated by XRPD. XRPD evaluation of solids isolated from the polymorph A input confirmed that hydrate A was successfully produced and that the solids dried to give polymorph A' from both drying methods. XRPD evaluation of solids isolated from the polymorph A' input confirmed that hydrate A was successfully produced and that the solids dried to remain as polymorph A' from both drying methods.

[0261] On the small scale investigated, polymorph A and polymorph A' will dry to give polymorph A' via conversion to hydrate A.

[0262] Psilocybin polymorph A (100 mg) was reduced in particle size using mortar and pestle grinding. To assess whether reducing the particle size affected the dehydration of the sample, the ground lot was subjected to two different drying regimes. The first sample was held at 80° C. for 10 minutes and the second sample was held at 110° C. for 10 minutes. Both solids were evaluated by XRPD which revealed that polymorph A was retained. It was considered whether the ground lot placed in the prior isothermal stress had not been held at 110° C. long enough to affect the morphology, and thus a portion of the ground lot was dried in vacuum at 110° C. for approximately 24 hours. Evaluation by XRPD revealed a slight change in morphology with the polymorph A reflection still present at approximately 17° C., albeit at a slightly reduced intensity.

[0263] It was concluded that polymorph A would not readily convert to polymorph A' via particle size reduction and / or drying at elevated temperatures. methodology

[0264] Stability evaluation of psilocybin free of pyrophosphate impurities showed that at temperatures above 80°C, the level of the stage 3 intermediate impurity (psilocin) generated by hydrolysis of psilocybin is of concern. For example, when an 83 mg / mL aqueous solution of psilocybin was heated to 90°C and analyzed by HPLC at 1, 2, and 4 hours, the level of the stage 3 impurity was measured to be 0.28, 1.82, and 7.79 area%, respectively. In comparison, when 50 mg of psilocybin was dissolved in water (1.2-1.8 ml; sufficient volume to maintain the solution) and heated to 70, 75, and 80°C for 4 hours, the level of the stage 3 impurity was measured to be 0.53, 0.74, and 2.30 area%, respectively, by HPLC. To achieve dissolution and polish filtration, recrystallization heats crude psilocybin to 75-80°C. Rapid cooling of the solution limits the level of psilocybin hydrolysis by reducing the residence time of the material at excessive temperatures.

[0265] Further trial recrystallizations of psilocybin were performed with the following changes introduced:

[0266] Vary the volume of water used;

[0267] Vary the agitation;

[0268] Has a controlled cooling profile;

[0269] Has a rapid (uncontrolled) cooling profile.

[0270] Using a smaller volume of water (only 12 volumes) did not impede the recrystallization process, and dissolution of psilocybin was achieved at a temperature that allowed for a polishing filtration step. Different cooling rates were shown to result in different crystal size distributions, with slow controlled cooling at approximately 10°C / hr resulting in a relatively larger and more uniform average crystal size (Figure 16a), whereas a rapid cooling profile gave smaller crystals (Figure 16b). The controlled cooling profile was preferred, and this was reflected in the improved purity for the controlled cooling.

[0271] Using this process resulted in psilocybin of 99.3% chemical purity in 75% yield. Thermal properties of the solids were consistent with the desired thermal properties. Differences in the XRPD diffractograms of the dried solids suggested that the drying profile may be important in determining how hydrate A disintegrates to give the preferred solid form. Polymorph A was demonstrated to be stable for 12 months under accelerated stability testing conditions.

[0272] experiment

[0273] Under N2, stage 5 was added to the vessel followed by water (approximately 12-15 volumes based on the active stage 5). To achieve dissolution, the mixture was heated to approximately 80°C and finish filtered through a 1.2 μm in-line filter into a clean new flask heated to 80°C. The stirring speed was set at a high level (450 rpm) and the solution was equilibrated at 70-75°C. At approximately 10°C / hr, the solution was cooled to ambient temperature and seeded with psilocybin hydrate A (0.001 x stage 5 loading) at 68-70°C. The suspension was maintained at ambient temperature overnight, then cooled to approximately 5°C and maintained for 1 hour. The suspension was filtered and washed with water (2-3 volumes based on the active loading of stage 5). The pure psilocybin was dried in vacuum at 50°C. Crystalline material psilocybin (polymorph A or polymorph A' depending on scale) was obtained and can be used to determine the crystalline form of psilocybin, e.g., Using a 94 g charge of psilocybin gave polymorph A, and using a 1 g charge of psilocybin gave polymorph A'. Typically, batch sizes greater than 5 g will yield polymorph A, while batch sizes smaller than 5 g will yield polymorph A'.

[0274] The differences and advantages from JNP can be summarized as follows: i) This additional crystallization step results in a defined crystalline form - polymorph A (or A'). ii) Heating to about 80° C. for a short period of time has the advantage that solubility is maximized (and hydrolysis is avoided), which ensures good yields. iii) At about 70-80°C, polishing filtration can be used to remove insoluble impurities. This is best accomplished with an in-line filter, typically around 1.2 μm. This ensures good chemical purity. iv) A high stirring speed (typically around 450 rpm) can be used to ensure rapid dissolution and minimize the time the solution is held at 80° C., thus avoiding increased levels of stage 3 intermediate impurities formed by hydrolysis of psilocybin. v) Providing controlled cooling, typically at about 10° C. / hr, results in a more uniform crystal size and maintains the morphology as crystalline hydrate A. vi) Seeding the solution with psilocybin hydrate A at about 70° C. promotes crystallization as hydrate A. vii) To maximize purity and yield polymorph A or A' depending on scale, the crystals are washed in water and dried at about 50°C. Examples 2 to 6 Stages 1-5: Psilocybin Production

[0275] As previously described herein, the following examples demonstrate significant departures from the process described in JNP and illustrated in FIG. [Example 2] Stage 1 (Figure 2)

[0276] Stage 1 conditions in JNP used 1.1 equivalents of Ac2O and 1.2 equivalents of pyridine in the solvent DCM. After stirring overnight the reaction was found to be complete (99% product, 0% starting material (SM)). The reaction mixture was washed with water and concentrated in vacuo to give a brown oil. In the literature the oil was taken up in EtOAc and concentrated by evaporation giving a solid precipitate at low volume. the study

[0277] However, in applicant's hands, no precipitation of solids was observed from EtOAc. Solid precipitation was promoted by trituration with heptane, but this would not form a scalable process. The solid was collected to give high purity Stage 1 product (75% yield, >95% pure by NMR).

[0278] Although the reaction worked well, the isolation procedure required further development so that an easily handled solid could be obtained. Isolation of the solid by filtration was then expected to provide a means for purification as well.

[0279] The reaction was first attempted in EtOAc to see if this could promote precipitation of the solid, allowing it to be isolated directly from the reaction mixture, however the reaction profile in EtOAc turned out to be more favorable than in DCM, and therefore this reaction was abandoned.

[0280] Applicants washed pyridine out of the DCM reaction mixture as it was believed to be inhibiting recrystallization of the product. The reaction was repeated (0.4% starting material, 98.7% product complete by HPLC) and the reaction mixture was washed with 20% citric acid to achieve pH 2 / 3, and pyridine was removed followed by saturated NaHCO3 (aq) to avoid low pH during the evaporation step. The organics were dried and a solvent switch to heptane was performed to obtain precipitation of stage 1. The solid was collected by filtration to obtain pure stage 1 after drying in vacuum (87% yield, >95% purity by NMR).

[0281] Stability tests were performed to confirm that the reaction mixture was stable overnight when also stirred with 20% citric acid and saturated NaHCO3. The product was found to be stable when oven dried at 40°C and 60°C. Scaling up

[0282] The Stage 1 reaction was successfully scaled up to process over 100 g of 4-hydroxyindole. The reaction proceeded as expected and was worked up to give the Stage 1 product (93% yield, ca. 98% NMR purity). GMP raw material synthesis

[0283] A large scale Stage 1 reaction was carried out (processing over 500 g of 4-hydroxyindole) to provide GMP starting material. The reaction proceeded as expected, giving consumption of starting material by HPLC (99.2% product, less than 0.1% starting material). The reaction was worked up using established procedures to give the Stage 1 product after drying (94% yield, 99.1% by HPLC, 99% NMR assay).

[0284] The Stage 1 technique was also noted during development to be effective in removing trace impurities present in some batches of 4-hydroxyindole. The low levels of impurities present in 4-hydroxyindole were completely removed after the Stage 1 reaction, giving clean material in high yield (89%) and purity (99% by HPLC and 99% by NMR assay).

[0285] experiment

[0286] Under N2, 4-hydroxyindole (1 eq. limiting reagent) was added to the vessel followed by DCM (dichloromethane; 6 volumes based on 4-hydroxyindole added). The reaction was cooled to 0-5°C and pyridine was added dropwise at 0-5°C (1.2 eq.). Acetic anhydride (1.1 eq.) was added dropwise at 0-5°C and the reaction was warmed to 20-25°C for 1-1.5 hours and stirred at 20-25°C for an additional 3 hours. The reaction was sampled and analyzed for completion. The reaction was then washed three times with 20% aqueous citric acid (3 x 3 volumes based on 4-hydroxyindole added) and once with saturated NaHCO3 (3 volumes based on 4-hydroxyindole added). The DCM solution was dried with MgSO4, filtered, and the DCM layer was concentrated to half volume by distillation. Heptane (6 volumes based on 4-hydroxyindole loading) was added and further DCM was removed by distillation until complete precipitation of Stage 1. The reaction was cooled to 15-25° C. and the solid was collected by filtration, washed with heptane (1 volume based on 4-hydroxyindole loading) and dried under vacuum at 60° C. overnight.

[0287] The differences and advantages from JNP can be summarized as follows: i) Applicant washed off the pyridine with citric acid at a pH of about 2-3. This facilitated improved isolation and crystallization. In practice, the DCM phase was separated and the aqueous citric acid phase was discarded. ii) Further washing in sodium bicarbonate gave further improvement. iii) Solvent switching to heptane improved solid precipitation, maximizing yield and resulting in reproducible high purity stage 1. [Example 3] Stage 2 (Figure 3) Step i - Formation of Acid Chloride

[0288] To determine whether it is a viable replacement for the volatile and highly flammable Et2O used in the literature, we first attempted the reaction of the Stage 1 product with oxalyl chloride (1.5 equiv.) in a mixture of TBME and THF (6 vol / 1 vol) to form the reactive intermediate 2A. The reaction was complete after approximately 18 h (Stage 1 in solution, precipitation of Stage 2A) with a solubility profile similar to Et2O.

[0289] Because the acid chloride intermediate is prone to hydrolysis, leading to variable analytical results, a more robust sample preparation and analysis was developed in which the reaction was quenched in THF / NMe2 (to give Stage 2) and then analyzed by HPLC.

[0290] The ratio of TBME and THF was optimized to give the highest purity and yield of intermediate, and a preferred ratio of 6:1 TBME:THF was selected for scale-up, although other ratios of TBME:THF may be used.

[0291] Large scale reactions were carried out using the preferred solvent mixture (1 vol THF, 6 vol TBME) but the addition of oxalyl chloride was carried out at 30-35°C. The resulting solution was then heated at 40°C for 2.5 hours and was complete with approximately 1% stage 1 product remaining. Carrying out the addition hot to maintain solution ensured high reaction rates and gave improved levels of completion in a much shorter reaction time (2.5 hours vs. overnight). The product was still seen to precipitate at temperature after approximately 15 minutes and no adverse effect on the reaction profile was observed by HPLC.

[0292] The stability of intermediate 2A was unknown, so rather than isolate the intermediate and risk decomposition (hydrolysis), an attempt was made to telescope the material to stage 2. The reaction profile was complex, with multiple components present at low levels. TBME was added and the precipitate collected. However, this was also found to be a complex mixture by HPLC / NMR.

[0293] Due to the poor reaction profile, it seemed necessary to isolate intermediate 2A to allow purification free of excess oxalyl chloride. The reaction was repeated and the yellow precipitate was collected by filtration and washed with TBME to remove excess oxalyl chloride (80% yield). NMR analysis confirmed that the product was of sufficient purity (approximately 95% by NMR). However, despite storage under nitrogen, some decomposition was observed over the following days, giving rise to partial hydrolysis including deprotection of the acetate group.

[0294] Further investigation of the telescoping approach was carried out to test and reduce the possibility of hydrolysis of the intermediate acid chloride upon isolation. It was found that the TBME liquid could be easily decanted by settling the reaction mixture, and the remaining solids were then washed in a similar manner with an additional portion of TBME. This allowed intermediate 2A to be purified free of excess oxalyl chloride while minimizing exposure to moisture.

[0295] Some reaction yield was lost due to partial dissolution of intermediates in the THF / TBME mixture. It appeared that a high yield could be achieved. This was confirmed by the addition of heptane to the decantation liquid, which gave rise to the precipitation of further solids. To limit this solubility, the addition of heptane (8 vol) was made prior to decantation. Rather than washing the solids with TBME, heptane was also used for washing (3×6 vol), which maximized the yield while maintaining the high purity of the intermediate. This methodology has been successfully scaled up and is the preferred process. Step ii - Reaction with dimethylamine

[0296] The literature (Synthesis, 1999, 6, 935-938; DE Nichols) suggested that HNMe2 gas would be effective for this transformation. However, to simplify large-scale processing, this was replaced with either solid HNMe2.HCl with an additional excess of base or a solution of HNMe2 in THF. JNP uses HNMe2 in the presence of an excess of base (pyridine).

[0297] The initially isolated intermediate 2A was used to optimize the reaction with dimethylamine through a series of test reactions (see Table 11).

[0298] [Table 11]

[0299] The literature-provided pyridine conditions (#1) were tried along with a similar reaction in EtO (#3), a biphasic reaction using MeNH.HCl and aqueous KCO (#2), and a reaction using excess 2M MeNH in THF (#4). In all cases, the major component by HPLC was the desired product, and the conditions using aqueous base and excess MeNH were generally much cleaner than those using pyridine. In all cases, significant hydrolysis products were seen, but this was believed to be the result of unreacted intermediate 2A being quenched during preparation of the sample for HPLC analysis. The reactions were worked up by addition of water, followed by removal of the organic solvent in vacuo to precipitate a solid.

[0300] Reactions with excess amine showed a much improved impurity profile, resulting in higher yields (72% vs. 63%) and purity (98% vs. 90%). This approach limited the water content of the reaction, thus minimizing the opportunity for hydrolysis to occur. It was also expected that purification would be easier due to the absence of pyridine in the isolated solid. For these reasons, conditions using excess HNMe2 as base were selected for scale-up.

[0301] The reaction in Et2O gave a clean (#4) profile. However, to facilitate large-scale processing, it became evident that it would be advantageous to switch to a less volatile solvent such as TBME. This was due to the fact that the acid chloride could be telescoped into the reaction. For these reasons, it was chosen to carry out the reaction in TBME with an excess of 2M Me2NH in THF.

[0302] It was thought that the addition of water would aid workup by solubilizing the HNMe2.HCl salt that was present resulting in a very thick mixture and slow filtration. This was tried. However, adding water to the reaction in TBME and THF gave poor recovery and analysis of the liquid showed additional impurities and extensive acetate deprotection (phenol product). Therefore, further development of purification was required. Refining Development

[0303] It was desirable to develop a purification strategy to remove the hydrolysis products and other impurities observed. It was also desirable to include water in the crystallization to reduce the salt content (assumed to be HNMe2.HCl) of the isolated material. To this end, a series of 15 solvents and solvent mixtures were screened (100 mg scale, 10 volume solvent, heating cycle to 60° C.).

[0304] [Table 12]

[0305] * The recovery is not representative since it was a thick suspension and the solids adhered to the glass vial.

[0306] From the solvents screened, acetone / water gave recrystallization with little observed solubility at room temperature, and since this was an aqueous system, it had the advantage of helping to purge the Me2NH.HCl from the solid.

[0307] The acetone / water recrystallization was scaled up. A solution was obtained at temperature (5 vol acetone, 1 vol water) before the addition of further water (4 vol) and the mixture was cooled to room temperature to give crystallization (62% Recovery, >99% HPLC purity). The process was then scaled up further by adding more water to aid in recovery (5 volumes total of acetone, 10 volumes water, 78% recovery).

[0308] This process was further scaled up (30 g) and the crude solid was collected via recrystallization techniques. The product was of high purity but there was a loss in yield (56% yield, 99% by NMR assay, 99.4% by HPLC).

[0309] To improve recovery, the amount of water added was further increased from 10 to 15 volumes. This maintained product purity above 99% and gave higher recoveries on a small scale (90% recovery, 56-70% previously observed). However, scale-up of this modified procedure again gave lower recoveries (58% yield). Therefore, due to the problems encountered when scaling up the recrystallization, based on the initial slurry screen performed (Table 12 above), alternative purification routes were explored.

[0310] The material isolated from the large-scale Stage 2 reaction was used to redevelop the purification strategy. The reaction proceeded as expected to give a crude product after oven drying (70% by NMR assay, 79% active material yield). A portion was slurried in water at room temperature to remove significant salt content (estimated to be HNMe2.HCl). After drying, this gave a 75% recovery (95% by NMR assay), indicating that this was an effective means of reducing the salt content. HPLC purity remained unchanged at approximately 93%. Methods to increase the chemical purity of the solid were then explored.

[0311] From initial screening, EtOH:H2O, IPA and Acetone:H2O all appeared to give high purity product with excellent recovery, so these solvent systems were selected for further study. The input purity was 92.7% with major impurities at levels of 1.4%, 1.0% and 0.8%.

[0312] [Table 13]

[0313] * The reaction was initially carried out in 5 volumes of 1:1 IPA:H2O, however, it became too thick to stir, so an additional 2 volumes of IPA were added.

[0314] ** The mixture was thick and the solids present were very fine, causing some solids to slip through the filter making filtration difficult.

[0315] The results of these tests suggested that good recoveries were possible from these systems, especially the IPA-based system. EtOH:H2O gave a slightly better impurity profile than IPA alone, but the recoveries were not as good (79 vs. 90%). The impurity profile with IPA was significantly enhanced by the presence of water (98.7% vs. approximately 97.5%), but this resulted in lower recoveries (79 vs. 90%). This suggested a certain level of water solubility for this compound. Final tests were performed in IPA and EtOH:water with reduced water volumes to see if a balance could be found that gave high purity and approximately 90% recovery. This system improved yields, but filtration was slow, so additional solvent mixtures were also evaluated.

[0316] [Table 14]

[0317] The 5 vol EtOH / water slurry was extremely thick and not easily handled. Since the purity of the solids was comparable across all trials (slight variations were likely due to the quality of filtration and washing), the 100% IPA condition was scaled up as it gave the highest recovery and the resulting suspension was easily handled.

[0318] Initial scale-up of the preferred slurry gave 96.4% HPLC purity (impurity levels of 1.2%, 0.7%, 0.4%) (92% recovery). Liquid analysis showed that they were enriched in all of the major impurities - 72% by HPLC (8.6%, 3.8%, 3.4%). This was considered an appropriate purification method giving high recovery so the following stages tested the use of this material to ensure that tracking and removal of impurities was achieved downstream (>99% in stage 3, no single impurity above 0.5%).

[0319] The remaining crude stage 2 material (70% assay) was slurried with water to remove inorganics and then slurried in IPA to give material of improved purity (97% by NMR assay, 76% yield relative to stage 2, 96.8% by HPLC, impurities at 1.1%, 0.8%, and 0.4%), and the slurry was found to be scalable. GMP raw material synthesis

[0320] To provide a GMP campaign, a large scale, stage 2 reaction was carried out. The reaction proceeded as expected to give a crude product which was slurried in water and filtered to give Stage 2 which was 93% pure by HPLC. This was further slurried in 8 volumes of IPA and filtered to give the Stage 2 product (93.7% by HPLC, 92% assay, 66% active material yield). The purity obtained was lower than that observed during the development campaign so a use trial was performed to confirm that the resulting high purity Stage 3 was suitable for further processing (GMP feedstock).

[0321] A second batch was run under identical conditions to give a crude product that was 90% pure by HPLC after water slurry. This material was subsequently purified by water slurry and IPA slurry to give 384 g of Stage 2 product (93.0% by HPLC, 91% by NMR assay, 60% active material yield).

[0322] A third batch was run to resupply the GMP synthesis. The crude product was successfully purified by water followed by IPA slurry to give Stage 2 (79% yield) with increased purity (97.3% by HPLC, 96% NMR assay) when compared to previous batches.

[0323] experiment

[0324] Stage 1 (1 equivalent limiting reagent) was added to the vessel under N2, followed by THF (1 volume relative to Stage 1 charge) and TBME (6 volumes relative to Stage 1 charge). Oxalyl chloride was then added dropwise to the vessel (1.5 equivalents), allowing an exotherm to initially raise the temperature to 35-40°C, then cooling was applied as necessary to maintain 35-40°C. Immediately after the addition, the reaction was heated to 40°C and stirred for 2-6 hours. The reaction was sampled and analyzed for completion, then cooled to room temperature and heptane (8 volumes relative to Stage 1 charge) was added, causing further precipitation of solids. The reaction was stirred for 10 minutes and then the solids were allowed to settle. The bulk of the solvent was removed from the solids by decantation, and the solids were then washed twice with heptane (6 volumes x 2 relative to Stage 1 charge), decanting in the same manner after each wash. The solids were then sampled and analyzed. TBME was added to the vessel (4 volumes relative to the stage 1 charge) to give a yellow slurry, which was cooled to −20° C. using a dry ice / acetone bath. A 2M solution of Me2NH in THF (2 equivalents) was added dropwise to the vessel over approximately 15 minutes, maintaining the temperature at −20° C. to −10° C. The reaction mixture was allowed to warm slowly to room temperature and stirred overnight. If necessary, additional Me2NH can be added at this point. The reaction was sampled and analyzed for completion. The reaction was filtered, washed with heptane (2 volumes x 2 relative to the stage 1 charge) and the isolated solid was dried under vacuum at 60° C. The crude stage 2 was slurried in water (8 volumes relative to the stage 1 charge) for 2-18 hours, then filtered and washed with water (2 volumes relative to the stage 1 charge). The solid was dried under vacuum at 60° C. to give crude stage 2 containing less than 2% w / w water (measured by Karl Fischer titration (KF)). Crude stage 2 was slurried in IPA (10 vol) for 2-18 h, then filtered, washed with IPA (1 vol with respect to crude stage 2 mass) and oven dried at 60° C. under vacuum.

[0325] The differences and advantages from JNP can be summarized as follows: Process 1 i) First, the use of the THF / TBME solvent system instead of diethyl ether was less volatile and flammable. ii) second, the addition of oxalyl chloride is carried out at elevated temperature, heating to 40°C; The improved solubility resulted in reduced entrapment of the Stage 1 product during precipitation, which also resulted in higher reaction rates, improved levels of completion, and shorter reaction times. iii) Third, intermediate 2A was isolated to allow purification free of excess oxalyl chloride. iv) Fourth, heptane was added to aid in the precipitation of intermediate 2A. Process 2 v) By ensuring that the amine is used in excess, greatly improved purity and yields were obtained due to the minimal amount of water present and therefore reduced hydrolysis. vi) Finally, the use of a water and IPA slurry gave a stage 2 product of good purity. [Example 4] Stage 3

[0326] An initial Stage 3 trial reaction was carried out using the purified Stage 2 material (>99% by HPLC) and the reaction conditions provided. The Stage 2 input material was found to be largely insoluble in THF, so rather than adding the Stage 2 solution to LiAlH4, a reverse addition was performed. 4 equivalents of LiAlH4 were used as a 1M solution in THF, and the addition was carried out at 20-25°C over approximately 2 hours. At this point, 10% product was observed, with several intermediate species present. The reaction was heated at reflux for approximately 7 hours to give 93% product conversion (by HPLC). The reaction was worked up to give the crude Stage 3 product (approximately 90% by HPLC, approximately 90% by NMR, approximately 87% corrected yield).

[0327] Test reactions were performed and the amount of LiAlH4 loading used was successfully reduced (3 vs. 4 equivalents). This was expected to aid in workup by reducing the amount of Li and Al salts produced. After extended heating at reflux (10-18 hours), the reaction intermediate was largely consumed (2-3% remaining) and approximately 95% product was obtained by HPLC. Post-processing development

[0328] The first pilot reaction was successfully worked up with Rochelle salt, but the volumes used were quite large (approximately 100 volumes) and this approach would not be a viable process for scale-up. A variety of alternative work-up approaches were investigated to try and reduce the volumes required and to aid in the removal of the Li / Al salts.

[0329] A reduced volume quench was attempted with EtOAc, then Rochelle's salt. A grey solid was present as a thick paste that settled to the bottom of the flask. Filtration failed, but the liquid could be decanted and the solid was reslurried in THF / EtOAc to extract the product. An aqueous workup was then performed and the product isolated by concentration. This gave the product in good yield (94% uncorrected for purity) and of good purity (90-95% by NMR). However, the process was not immediately amenable to scale-up.

[0330] The reaction was quenched by the addition of EtOAc, then saturated Na2SO4, in the presence of anhydrous Na2SO4 to act as a coupling agent. The reaction gave a granular solid that could be easily filtered. An aqueous workup was then performed and the product was isolated by concentration. A good yield was obtained (approximately 94% uncorrected for purity), but the product contained higher levels of the major impurity by NMR (10% vs. the typically observed 2-4%).

[0331] The reaction was quenched with 20% AcOH at 0° C., resulting in the formation of a gel that could not be filtered. The reaction was abandoned.

[0332] The reaction was quenched with EtOAc, then 20% citric acid to give a solid that could be isolated by filtration. The liquid was concentrated to give the product. This procedure gave a slightly lower yield (approximately 77% uncorrected for purity), but the product was of extremely high purity (>95%).

[0333] Further reaction was quenched by addition of EtOAc followed by water (3 mL per g LiAlH4 in THF). A gel formed that was not easily filterable and the reaction was abandoned.

[0334] Finally, the reaction was quenched by the Fieser method: addition of water (1 mL per g LiAlH4), then 15% NaOH (1 mL per g LiAlH4), and finally water (3 mL per g LiAlH4). This gave a solid that could be filtered from the reaction mixture. The liquid was then partitioned and concentrated in vacuo (87% yield, 90-95% by NMR).

[0335] These experiments are summarized in Table 15 below.

[0336] [Table 15]

[0337] Both citric acid and NaOH quenching gave solids that could be easily filtered from the reaction mixture and required minimal solvent volume. The NaOH condition gave a higher yield (approximately 10%), but the product obtained from this procedure was less pure and may require further purification before use in the next stage. The lower yield with citric acid could be due to some precipitation of the product citrate salt. This had a purifying effect, and clean product was obtained immediately after concentration. These conditions were selected for scale-up, and further optimization of the citric acid loading was expected to allow for isolation of clean product in high yield from this process.

[0338] The reaction was repeated with a slightly reduced citric acid loading to attempt and maximize recovery. This reaction gave the product in 57% yield, with an additional 20% yield obtained by reslurrying the filter cake in THF (97.7% for both samples by HPLC).

[0339] This reaction was scaled up. However, during the EtOAc quench, which had previously been seen to thicken the reaction, it gummy in the flask and formed a thick mass that restricted mixing. Addition of citric acid then resulted in the usual slurry / gel, but this was not a viable process. This reaction was worked up to maximize recovery by reslurrying the filter cake in THF to give 76% active material yield, 95.0% by HPLC.

[0340] The reaction was repeated to develop a better quench and avoid the formation of a gummy material seen with EtOAc. A portion was quenched by addition of acetone, which resulted in an easily stirred suspension / emulsion with no signs of thickening. A citric acid treatment was then performed to give a filterable mixture. This quench was successfully performed on the remainder of the reaction and worked up to give the crude product in good yield (71% assay, 82% corrected yield, 98.0% by HPLC).

[0341] After quenching, the reaction mixtures were found to be generally pH 8 / 9. As part of the workup optimization process, different pHs were investigated. The reactions were split for workup, with half receiving a slightly reduced citric acid loading (to obtain a pH of 11 / 12 after quenching) and the other half brought to pH 7 by the addition of additional citric acid. The pH 11 reaction was worked up to give material with 85% NMR assay (73% yield) and the pH 7 reaction gave 60% NMR assay (62% yield). It was clear from this result that obtaining the correct pH after quenching was critical to give a yield above 70%. By only slightly reducing the citric acid loading (still approximately 2 volumes of 20% citric acid), an approximately 8% increase in yield was obtained. With this information in hand, the pH of future reactions was monitored during the quench to ensure the mixture remained strongly basic. Refining Development

[0342] A purification screen was performed using 100 mg portions of the crude psilocin product slurried in 10 volumes of solvent with a heating cycle of 60° C. The slurry was cooled to room temperature over the weekend and any solids were then collected by filtration. Stability to acids and bases was also tested with the aim of performing an acid / base workup. The results of the screen are shown in Table 16 below.

[0343] [Table 16]

[0344] The first of the three highlighted impurities corresponded to the most stable reaction intermediate (requiring reflux for conversion to product) observed at approximately 70% when LiAlH4 addition was complete. The third impurity was not present in the charge and was likely generated during the slurrying procedure. Of the solvent that remained in the slurry, iPrOAc gave the highest purity. Some recrystallization was found, but MeCN had the potential to remove impurities during crystallization and had recoveries that could be improved during development. Some decomposition was observed in both acid and base, and the KOH sample turned black quickly.

[0345] The two most promising solvents (MeCN and i The purification of crude Stage 3 material was scaled up using 1,2-dichloro-2,4-diphenyl-2,4-tetrahydrofuran (PrOAc). The solvent volume was reduced to a minimum to improve recovery. The results of these trials are shown in Table 17 below.

[0346] [Table 17]

[0347] Recrystallization was obtained from 5 volumes of MeCN and hot slurry was achieved in 3 volumes of iPrOAc. (both at 75 °C). Despite the reduced volume, recoveries from MeCN were similarly poor, but the product was of very high purity (>>95% by NMR). Recoveries from iPrOAc were better, with a large increase in product purity (approximately 95%) as analyzed by NMR.

[0348] Although the HPLC and NMR purity of the material from the iPrOAc slurry was high, a low assay value (85% by NMR assay) was observed. To improve the assay value of the material and to remove the color (all material obtained so far has been strongly purple, green or brown), purification by silica pad was investigated.

[0349] The crude psilocin (71% assay, 98.0% by HPLC) was passed through 4 equivalents of silica and eluted with THF. An off-white solid was obtained in 80% recovery with slightly improved HPLC purity (98.4%) and assay (approximately 82% assay). This proved to be an effective means of increasing the assay value of the product and was therefore included as part of the reaction workup.

[0350] A series of runs were then performed using silica-treated feed (100 mg / slurry) to try and improve recovery while maintaining chemical purity (feed purity 98.4%). i A PrOAc / anti-solvent slurry (Table 18) was performed.

[0351] [Table 18]

[0352] Since all purity values ​​were comparable, two solvent systems were selected for scale-up based on the highest recovery obtained. Two preferred slurries (TBME and toluene as anti-solvents) were scaled up (1.0 g per slurry) to better evaluate the recovery rates.

[0353] [Table 19]

[0354] Combined with a silica pad, it gives material of >99% HPLC purity with approximately 80% recovery. Both of these options presented appear to provide effective purification avenues for the psilocin product. During slurrying, additional color was transferred into the liquid, and psilocin was obtained as a white solid. All impurities were effectively removed to less than 0.5%. Non-toxic ICH Class 3 solvents were used, making it feasible to use for scale-up. i The PrOAc:TBME slurry was chosen. Scaling up

[0355] The developed Stage 3 conditions were scaled up and the reaction proceeded to 94.4% completion with 2.9% reaction intermediates by HPLC after overnight at reflux (typical for this process). After a silica pad, psilocin was obtained in 83% purity by NMR assay, 66% active yield, and 97.0% by HPLC. This material was further purified by slurrying in iPrOAc / TBME to give material in 62% yield, 100% by NMR assay, and 99.7% by HPLC.

[0356] Since the crude yield from this reaction was lower than expected (66% vs. approximately 75%), the filter cake and silica pad were retested in an attempt to recover more material, however, this was unsuccessful.

[0357] The lower than expected yield could have been due to product decomposition during workup, but preliminary stress tests showed that the material was stable under the conditions used. To investigate this further, the reaction was repeated. To ensure that no product decomposition occurred during workup, the crude product was isolated before the silica pad and further stress test samples were taken.

[0358] The reaction proceeded as expected to completion (93.7% product, 2.9% intermediate) and was concentrated to give crude material (77% NMR assay, 66% active yield). The filter cake was reslurried in THF / MeOH, but no significant psilocin was isolated. To try and displace any product coordinated to the aluminum salt, more citric acid was added to bring the pH to 4 (from pH 8) and the cake was reslurried in THF, but again no significant psilocin was isolated. A mass balance was not obtained from the reaction, and the 66% active yield was in good agreement with that obtained previously. Silica pads and i The batch was purified by slurrying in PrOAc / TBME to give a 62% yield of highly pure material (99.8% by HPLC).

[0359] Although the solvent volumes used were relatively large and a silica pad was required for removal of aluminum and lithium species, the process was still quite suitable for the scale required.

[0360] The Stage 3 reaction was further scaled up for workup. The reaction proceeded as expected and was complete after 18 hours (approximately 91% product, approximately 3% reaction intermediates remaining). Workup on a silica pad and slurrying gave 57% yield of highly pure psilocin (>99% by HPLC, 99% NMR assay, 0.35% w / w water Karl Fischer).

[0361] experiment

[0362] Stage 2 (1 equivalent of limiting reagent) was added to the vessel followed by THF (5 volumes relative to the amount of Stage 2 added). The mixture was cooled to 0°C and a 1M THF solution of LiAlH4 (3 equivalents) was added dropwise over 30-45 minutes while maintaining the temperature between 0-20°C. After the addition, the reaction was stirred at 10-20°C for 30 minutes and then heated to reflux and allowed to stand for approximately 16 hours. The reaction was sampled, analyzed for completion, cooled to 0°C, and quenched by dropwise addition of acetone (9.3 eq.) at 0-30°C, followed by 20% aqueous citric acid (1.9 vol. per stage 2 loading) at 0-30°C. The pH of the addition was monitored to ensure it remained >11, and the addition was stopped early if necessary. The resulting suspension was stirred for 1 hour, filtered, and washed with THF (2 vol. per stage 2 loading) to remove Li and Al salts. The filter cake was slurried in THF (12.5 vol. per stage 2 loading) for approximately 1 hour, filtered, and washed with THF (5 vol. per stage 2 loading) to recover the product from the Li and Al salts. The combined organics were dried over MgSO4 and filtered. The filtrate was evaporated in vacuum until approximately 10 vol. remained (per stage 2 loading), and the solution was applied to a silica pad (3 eq. per stage 2 loading). The silica pad was eluted with THF and the product fractions were combined and evaporated to dryness in vacuo. The crude stage 3 (psilocin) was slurried in 1:1 iPrOAc:TBME (5 volumes relative to the step 18 mass) for 2-18 hours, filtered, washed with TBME (2.5 volumes relative to the step 18 mass) and dried in vacuo at 40°C to isolate pure psilocin.

[0363] The differences and advantages from JNP can be summarized as follows: i) First, applicants used THF as the solvent but quenched the reaching with acetone, which results in a suspension / emulsion without thickening. ii) Second, applicants quenched with citric acid while maintaining a basic pH, typically around 11. The pH adjustment ensured that high yields were obtained. iii) Third, purification by silica pad to remove residual Li / Al salts, followed by elution with THF and slurrying in iPrOAc:TBME gives a highly purified product which is then dried. [Example 5] Stage 4

[0364] Literature conditions were first used to work up a 2.58 g sample, giving approximately 88% conversion to intermediate 4A as analyzed by HPLC. The product was purified by addition of aminopropyl silica and filtration through Celite. Slurrying the resulting green oil (5.5 g) in DCM afforded benzylic rearrangement and precipitation of the zwitterionic stage 4 (4.1 g, 70% yield, approximately 95% by NMR). Process i

[0365] Initial developments at this stage will be more tractable and ideally will not introduce additional lithium during synthesis. n The focus was on finding replacements for BuLi. t BuO, K t An initial screen of alternative conditions was performed, including BuO, NaH, NaHMDS, and NaNH2. All of the reactions gave products, with NaHMDS giving n Worked just as well as BuLi. All of the reactions became very thick and gelling was observed, overhead stirring is recommended for efficient mixing.

[0366] The first screening was performed with NaHMDS. n These conditions suggested that this was a suitable alternative to BuLi (81% conversion to product / intermediate 4A). n In parallel with the reference reaction using BuLi, it was scaled up to 1.5 g. In both cases overhead stirring was used.

[0367] [Table 20] Abbreviations used in the table: St 3 = stage 3, Int 4A = intermediate 4A, St 4 = stage 4

[0368] The reaction profiles obtained in both cases were very similar to the NaHMDS reaction consuming stage 3. Both reactions were filtered through Celite and concentrated to remove the white precipitate. NMR showed ( nExcess benzylic protons were present in both cases (especially with BuLi) and the isolated yields were greater than 100%. NaHMDS conditions gave a favorable reaction profile, proved successful, and were selected for further scale-up. However, work-up and purification required development. Process ii

[0369] HPLC data shows that the material isolated from the above trial using NaHMDS and n BuLi was shown to rearrange and upon concentration to give the zwitterionic stage 4. Purification of this material to remove benzyl phosphate by-products and other impurities was attempted by slurrying in a number of solvents.

[0370] [Table 21] Abbreviations used in the table: St 4 = Stage 4

[0371] * Poor filtration

[0372] White solids were obtained from several solvents, but the solids from DCM and TBME turned to a light purple gummy material when stored over the weekend. The white solids from IPA and acetone remained free-flowing white solids on storage, suggesting that these solids may be more stable and allow for easier handling.

[0373] The slurry in IPA and acetone was scaled up to 1 g. However, gummy formation was observed immediately upon addition of the solvent. With vigorous stirring, the gummy material slowly dispersed and eventually showed signs of crystallization, forming a white slurry after stirring overnight. Therefore, this process was not amenable to scale-up. Solids were isolated in good yields using IPA, which gave the highest purity.

[0374] THF was also investigated as it had the advantage of being the reaction solvent. However, when this was tried, initial gum formation was again observed (approximately 80% yield, isolated in approximately 92% by HPLC). To try and avoid gum formation and give a more controlled crystallization, crude stage 4 was first solubilized in a low volume of DMSO (2 volumes). THF was then added to this (10 volumes) and the solution was stirred over the weekend. This gave a slow precipitation of the product which was collected by filtration and washed with THF to give stage 4 (86% yield) in 96% HPLC purity (>95% by NMR).

[0375] Since THF crystallization was successful and it was previously observed that complete conversion to the zwitterionic stage 4 occurred upon concentration of the reaction (THF / EtOAc) at 40 °C, it was expected that a change of solvent could be avoided and the product could be directly crystallized by stirring the reaction mixture at 40 °C.

[0376] Two 4 g NaHMDS reactions were carried out with both reactions and reached completion with approximately 80% conversion to intermediate 4A. One reaction was diluted with EtOAc, the other with THF, and both were filtered to remove the phosphate by-product. To further reduce the phosphate impurity level, a brine wash was performed and the organics were dried and concentrated to 10 volumes. The solutions were stirred overnight at 40° C., resulting in conversion and precipitation to stage 4 (approximately 1% stage 3, approximately 0.2% intermediate 4A, approximately 82% stage 4). The solids were collected by filtration to give 8.03 g (88% yield) from EtOAc / THF and 5.65 g (62% yield) from THF. The brown / gray solid obtained from EtOAc / THF was less pure (approximately 90% by HPLC, 78% assay) compared to the white solid obtained from THF (97% by HPLC, 88% assay). Analysis of the aqueous layer from the THF reaction showed the presence of product with additional losses in the final THF filtrate.

[0377] Due to the higher purity obtained from THF, this solvent was further explored to optimize recovery. Due to loss of product into the aqueous layer, the brine wash was omitted and the reaction mixture was further concentrated after the reaction to minimize losses during the final filtration step. This new approach was tried on a 75 g scale by concentrating portions of the reaction mixture to 8 and 6 volumes. Upon filtration, no difference in yield was observed between the two portions, with a total yield of 140.4 g (90% by NMR assay, 74% active material yield, 90% by HPLC). Impurity Tracking

[0378] Three major impurities were observed in the isolated product and the identities of two of these species were proposed based on MS data.

[0379] The debenzylated impurity (typically around 2-5% by HPLC) was shown to give psilocybin during the following hydrogenation and therefore could be tolerated at higher levels. The main observed impurity in isolated stage 4 (typically around 5-8% by HPLC) was an anhydride impurity. This was followed through the subsequent hydrogenations and shown to be easily removed by recrystallization from water as a highly soluble pyrophosphorate impurity resulting from debenzylation. The other major observed impurity (m / z 295.2 observed by LCMS) was found to be controlled to less than 2% by constraining the reaction temperature (below -50 °C) and was not observed in psilocybin after hydrogenation.

[0380] The impurity profile of the 140 g batch produced above showed 90.0% stage 4, 6.4% anhydride impurity, 0.2% N-debenzylated impurity and 1.2% m / z 295.2 impurity. GMP synthesis

[0381] Using established procedures, the first large scale stage 3 batch (544 g input) was completed to give 213.5 g (53% yield, 99% by HPLC). The second batch (628.2 g input) was also successfully processed to give 295.2 g (66% yield, 99% by HPLC).

[0382] Some variation in yields at this stage was observed across the three large-scale batches (57%, 53%, and 66%), likely the result of minor differences in workup and quenching procedures.

[0383] experiment

[0384] Stage 3 was added to the vessel followed by THF (15 volumes relative to the Stage 3 addition) and cooled to below -50°C using a dry ice / acetone bath. A 1M solution of NaHMDS in THF (1.13 equiv.) was added while maintaining the temperature below -45°C, targeting below -50°C. The reaction was stirred at -60 to -50°C for 30 minutes. Tetrabenzyl pyrophosphate (2.26 equiv.) was added to the reaction in one portion followed by additional THF (20 volumes) while maintaining the reaction temperature below -30°C. The reaction was warmed to 0°C over 1.5-2 hours and sampled to check for completion. The reaction was filtered to remove the phosphate salts, washing with THF (8 volumes). The filtrate was concentrated until 6-8 volumes remained and stirred at 40°C overnight to convert Intermediate 4A to the Stage 4 product. The reaction was sampled to check for completion, then filtered and the solids washed with THF (2 volumes). The Stage 4 product was dried in a vacuum oven at 40°C.

[0385] The differences and advantages from JNP can be summarized as follows: Process i i) First, sodium hexamethyldisilazane was introduced to aid in deprotonation, which proved to be a useful alternative to butyllithium, being easier to handle and not introducing additional lithium into the reaction. ii) Secondly, by diluting the reaction with THF, intermediate 4A was obtained in much higher purity. iii) Third, by controlling the reaction temperature below -50°C, the undesired mz295.2 observed by LCMS was controlled to a level below 2%. Process ii iv) Fourth, by monitoring the levels of Stage 4A impurities, particularly N-debenzylated Stage 4 (Table 7) and anhydrous Stage 4 (Table 7), pure product can be reproducibly produced. v) Conversion of intermediate Stage 4A to Stage 4 can be carried out in the reaction solvent, avoiding the need for time-consuming solvent exchanges. vi) Finally, the obtained solid is washed with THF and oven dried to obtain stage 4. [Example 6] Stage 5

[0386] If catalyst poisoning is observed during development of this stage and is needed to suppress incomplete hydrogenation, a charcoal treatment step should be included in the process. However, activated carbon treatment is not routinely required.

[0387] After sparging with hydrogen for 3 hours, a typical reaction showed a high level of completion (>90% product, 3-5% starting material remaining). A small amount of water was added to aid solubility, and after sparging with hydrogen for an additional hour, stage 4 consumption was achieved.

[0388] Successful reactions were worked up by filtration followed by evaporation to remove the methanol, leaving the product as a thick suspension in water. Ethanol was added and the solid was filtered to give psilocybin in 69% yield. 1H NMR confirmed the identity of the product but indicated the presence of trace amounts of related impurities. LCMS analysis showed a purity of 95.2% with the major impurity (4.1%) identified as a pyrophosphate impurity (Table 7) originating from an anhydride impurity in stage 4. This impurity was later shown to be effectively purged during recrystallization of the final product (stage 6).

[0389] Further reactions were then carried out using the Stage 4 material from the final THF workup, which was 88.0% pure by HPLC, contained 7.3% N-debenzylated Stage 4 (converted to product), and was free of anhydride impurities. Again, completion was observed and the reaction was worked up as previously described to give psilocybin in 46% yield. The low yield was believed to be due to precipitation of the product during the catalyst filtration step. 1 H NMR confirmed the identity of the product and HPLC showed a purity of 98.9%.

[0390] Further development of the reaction conditions was carried out to optimize the volume of water used and minimize product loss during the filtration step. After the reaction, a solution was obtained by adding 10 volumes of water while heating to 40° C. This allowed the catalyst to be removed by filtration without product loss on the filter.

[0391] During the reaction and workup, some stage 3 was produced by hydrolysis, with levels of approximately 1-2.5% appearing to be typical for the process. A decrease in stage 3 levels was demonstrated during final recrystallization of the product. Scaling up

[0392] The large scale stage 4 batch (non-GMP) was processed as a single batch (148 g active input). Stage 4 consumption was achieved with 88% product and 0.9% stage 3 due to hydrolysis. The anhydride impurity (6.4%) was completely converted to the corresponding pyrophosphate impurity (5.2%).

[0393] The bulk hydrogen adduct was filtered and concentrated to give 109 g of crude product after stripping from ethanol to reduce the water content (approximately 71% by NMR assay, 86% yield). experiment

[0394] 10% Pd / C (approximately 50% water wet, Type 87 L, 0.1× Stage 4 addition volume) was added to the vessel under N2, followed by methanol (20 volumes for Stage 4) and Stage 4. The N2 was replaced with H2 and the reaction was stirred under H2 (atmospheric pressure) for 1-2 hours. The reaction was sampled to check for completion, then water was added (10 volumes for Stage 4) while maintaining the temperature below 25° C. The mixture was stirred under H2 (atmospheric pressure) for an additional 1-2 hours. The reaction was sampled to check for completion.

[0395] If the reaction was incomplete, H2 was added again and the reaction was continued for an additional 1-12 h until completion was observed. The reaction was then placed under N2, warmed to 40 °C, and stirred for 15-12 h. The reaction was maintained for 45 min. The reaction was filtered through Celite to remove the catalyst and washed with methanol (13.3 vol. for Stage 4 charge) and water (6.7 vol. for Stage 4 charge). The filtrate was concentrated in vacuo and azeotroped with ethanol to remove water until a solid was obtained. The differences and advantages from JNP can be summarized as follows:

[0396] Primarily, the reaction is monitored for intermediate levels by HPLC using relative retention time (RRT) to control completion with intermediates present at less than 0.2%. Stage 5 pyrophosphate impurity is also closely monitored to ensure it can be controlled in the final recrystallization.

[0397] The final stage 6 process is as described in Example 1. [Example 7] Test Methodology and Protocol

[0398] To test for purity etc. the following methodology / protocol was utilized. 7.1 NMR

[0399] Using a 400 MHz spectrometer, 1 H and 13 The C NMR spectrum was obtained. The chemical shifts were: 1 In H NMR, the values ​​are in ppm relative to DO (□=4.75 ppm). 13 C NMR spectra are reported in ppm relative to MeOH (□=49.5 ppm) added as a reference. Literature values ​​for psilocybin are reported in JNP. Analysis of psilocybin by NMR gave data that are consistent with the structure and those reported in the literature, with only minor variations in chemical shifts for protons near ionizable groups, although this variation is expected since the zwitterionic nature of the compound makes this material extremely sensitive to small changes in pH.

[0400] 1 H NMR and 13 The C NMR data is summarized below and the spectra are shown in Figures 10 and 11.

[0401] 1 H NMR data (400MHz, D2O): 2.79 (s, 3H), 3.18 (t, J=7.4Hz, 2H), 3.31 (t, J=7.4Hz, 2H), 6.97 (d, J=8.0Hz, 1H), 7.08 (s, 1H), 7.10 (t, J=8.0Hz, 1H), 7.19 (d, 8.2Hz, 1H).

[0402] 13 C NMR data (400 MHz, D2O (+ traces of MeOH): 22.3 (1 x CH2), 43.4 (2 x CH3), 59.6 (1 x xCH2), 108.4 (1 x CH), 108.6 (1 x C), 109.5 (1 x CH), 119.1 (d, 3 J P-H=6.7Hz,1 x C), 123.3(1 x CH2), 124.8(1 x CH), 139.3(1 x C), 146.3(d, 2 J P-H =6.7Hz,1 x C) 7.2 FT-IR

[0403] Data was collected on a Perkin Elmer Spectrum Two™ Spectrometer equipped with a UATR Two accessory. Analysis of psilocybin (batch: AR755) by FT-IR spectroscopy gave a spectrum ( FIG. 12 ) consistent with the proposed structure. -1 The broad peak at is typical for an amine salt. The remainder of the peaks are in the fingerprint region and therefore cannot be individually assigned. 7.3.Mass spectrometry

[0404] The mass spectrum of psilocybin (AR755) was obtained on a Bruker Esquire 3000 plus Ion Trap Mass Spectrometer and was consistent with the structure. The mass spectrum (Figure 13) shows the (M+H) + and (2M +H) + The main peaks corresponding to psilocybin (C) were shown at m / z = 284.8 and 568.1. This is because this molecular ion corresponds to the molecular formula of psilocybin (C 12 H 17 The results suggest that the tetrahydrofuran has an m / z of 284, which corresponds to N2O4P (Figure 14). 7.4 Ignition residue

[0405] The ignition residue method follows the Pharmacopoeia method with one adjustment: when the crucible was heated to 500°C, inconsistent results were obtained. This was believed to be due to the low volatility of the phosphate residues produced. Therefore, for psilocybin, the temperature was increased to 800°C, which gave consistent and accurate results. 7.5 HPLC-Assay and Purity Determination

[0406] The HPLC method used to quantitate psilocybin assay, chemical purity and impurities is a gradient HPLC-UV method, and the conditions are summarized in Table 22. An external standard is used for quantitation. Approximately 1 mg / mL of psilocybin was dissolved in purified water:MeOH (95:5). Sonicate to completely dissolve.

[0407] Purity by HPLC is calculated based on area % and correlated to known retention time standards.

[0408] Assays by HPLC are calculated on an anhydrous basis based on weight percent relative to standards of known purity and composition.

[0409] [Table 22] 7.6 Residual Solvent Content by HRGC

[0410] The HRGC method for determining residual solvents is the headspace method and is set forth in Table 23 below.

[0411] [Table 23]

[0412] The levels of the following solvents and reagents are measured: methanol, ethanol, THF and toluene. 7.7 Melting point by DSC

[0413] DSC data were collected on a PerkinElmer Pyris 6000 DSC (or similar). Certified indium was used to verify the instrument for energy and temperature calibration. Samples were weighed (typically 0.5-3.0 mg) into pinhole-punched aluminum sample pans. An aluminum pan cover was used to crimp the pans. The pans were heated at 20°C / min from 30 to 300°C while purging with dry nitrogen at 20 mL / min. During the melting point procedure, each batch of psilocybin polymorph A or A' exhibited two endothermic events, the latter of which was attributed to the solid-solid transition of polymorph A or A' to polymorph B, and the second of which was attributed to the melting of polymorph B. 7.8 Polymorphism by XRPD

[0414] The solid state form of psilocybin is determined by XRPD. XRPD diffractograms were collected on a diffractometer (such as a PANalytical X'Pert PRO or equivalent) under ambient conditions using Cu Kα radiation (45 kV, 40 mA), a θ-θ goniometer, a focusing mirror, a divergence slit (½ inch), and Soller slits (4 mm) for both the incident and diverging beams. The data collection range was 0.2° s -1 The diffractograms were measured at a continuous scan rate of 0.05 μm from 3 to 35° 2θ. The resulting diffractograms were compared to those of reference diffractograms of polymorphs A or A' to ensure agreement (Figures 7a or 7b, respectively). 7.9 Thermogravimetric analysis (TGA)

[0415] TGA data was collected on a PerkinElmer Pyris 1 TGA (or similar). The instrument was calibrated for temperature using certified weights and certified Alumel and Perkalloy. A predetermined amount of sample (typically approximately 5 mg) was loaded into an aluminum crucible and heated from ambient to 400° C. at 20° C. / min. A nitrogen purge at 20 mL / min was maintained over the sample. 7.10 Loss on drying

[0416] Loss on drying of samples is determined in duplicate using accurately weighed 1 g aliquots and dried under vacuum at 70° C. to constant weight.

[0417] Calculation:

number

[0418] Psilocybin drug substance was stressed under a variety of conditions, both in solution and in the solid state, to provide samples for evaluating analytical method selectivity.

[0419] Forced degradation studies were performed on psilocybin based on the requirements of ICH Q1A(R2). The study under stress conditions provided information on the possible degradation pathways and intrinsic stability of psilocybin. The optimized analytical method used demonstrated specificity for psilocybin. The analytical method was shown to be suitable and can be used to detect changes to the identity, purity and potency of the product. The method used meets ICH Q2(R1) (analytical procedure validation) in terms of specificity and also showed the absence of interference from possible impurities and degradation products. Therefore, the HPLC method is considered suitable to measure the purity and associated impurities of psilocybin.

[0420] The psilocybin control sample was stable in solution over the study period (for the non-photostable sample, the study period was 7 days). When heated in solution, psilocybin slowly decomposed to produce psilocin as the main impurity. Psilocybin was also stable under acid conditions at room temperature. However, at 60°C, slow and steady decomposition was observed to produce psilocin as the main impurity. In the presence of base, psilocybin was slightly unstable at room temperature and slowly decomposed into various impurities over the study period. Under peroxide conditions, only very low levels of impurities were formed, with the overall purity decreasing by approximately 0.5%. In the solid state, slow chemical decomposition was observed (3 days at 150°C) to produce mainly psilocin (stage 3) as an impurity. Psilocybin was stable under photostable conditions both as a solid and when in solution. Stability testing

[0421] A stability study was undertaken with two batches of psilocybin, as shown in Table 24.

[0422] [Table 24]

[0423] Samples were double bagged in food grade polythene bags, sealed in outer polyethylene containers and stored at 2-8°C, 25°C / 60% RH and 45°C / 75% RH with a desiccant bag included between the inner polyethylene bags to prevent moisture uptake. Appearance, water content, purity and assay tests were performed.

[0424] The protocols for the two studies are shown in Tables 25 and 26. The 1-month and 3-month stability data for batch GM764B is detailed below in Tables 27 and 28. The 1-, 3-, 6-, 9- and 12-month stability data for GMP batch 170231 is provided below in Tables 29, 30, 31, 32 and 33, respectively.

[0425] [Table 25]

[0426] [Table 26]

[0427] [Table 27]

[0428] [Table 28]

[0429] [Table 29]

[0430] [Table 30]

[0431] [Table 31]

[0432] [Table 32]

[0433] [Table 33]

[0434] Over the first 12 months of the ICH stability study, psilocybin was chemically stable under low temperature (2-8°C), ambient (25°C / 60% RH), and accelerated (40°C / 75% RH) conditions. There was no change in appearance and the HPLC analysis remained consistent. The water content varied in all samples due to initial effects and then due to deterioration of the desiccant packets used in the testing. Example 9 - Experiment to form Hydrate A

[0435] Psilocybin (200 mg) was added to the crystallization tube, followed by deionized water (4 ml). After equilibrating the mixture at 25° C. for 2 hours, the solid was isolated by vacuum filtration. The material was divided into two equal portions. One portion was not subjected to further drying to give Hydrate A, Lot GK2, by XRPD and DSC (diffractogram and thermogram matching Figures 7d and 8d, respectively). Example 10 - Experiment to form polymorph B

[0436] A round bottom flask was charged with psilocybin polymorph A (250 mg) and heated to 173° C. using an oil bath and maintained at this temperature for 5 minutes. The solid was cooled to ambient temperature and isolated to give lot GK3 in 93% recovery. Analysis by XRPD and DSC (diffractogram and thermogram matching Figures 7c and 8c, respectively) revealed that lot GK3 was polymorph B. Example 11 -Solid State Testing

[0437] A number of polymorphic studies were completed. A summary of the solid forms found is shown in Figure 17. The majority of the forms found were due to solvent perturbation. In some cases, stoichiometric solvates were isolated and in other cases, non-stoichiometric solvates were isolated. Polymorph A slurry

[0438] Solvent-mediated equilibration of psilocybin Pattern A was performed as a primary route to modification of the solid form and to visually assess the solubility of the material in a variety of 24 solvents at 25-50 °C.

[0439] At room temperature, psilocybin Pattern A (40 mg) was added into the tube and the solvents listed in Table 34 were added in 0.4 ml (10 vol) aliquots up to a total volume of 1.2 ml (30 vol) and observations noted. The mixture was constantly stirred. Thermal cycling was performed as follows: 50° C. for 18 hours, cool to 20° C. over 2 hours, age for 4 hours, heat to 50° C. for 4 hours, cool to 20° C. over 2 hours, age for 18 hours. Repeated 50° C.-20° C. cycles over 24 hours were performed applying the following: Isolation after heating to 50°C, if there is enough solid = Series A Isolate after cooling to 20°C, if there is enough solid = Series B All isolated solids were dried in vacuum at 50° C. for 24 hours and analyzed by XRPD. Observations are given in Table 34.

[0440] In the solvents and solvent mixtures tested at 30 volumes and 50° C., the API was largely insoluble, resulting in heavy suspensions. Water solubilized psilocybin at 50° C.

[0441] [Table 34]

[0442] result:

[0443] In the figures (Figures 18 and 19), "25C" represents isolation of the solid at 25° C. and "50C" represents isolation of the solid at 50° C. For example, GM832-20_50_A9 represents GM832 entry 20 (MeCN) isolated at 50° C.

[0444] 50℃ Slurry

[0445] Entries 1, 2, 3, 4, 5, 7, 8, 10, 11, 13, 14, 15, 16, 22, 23, 24: XRPD diffractogram broadly consistent with polymorph A, but with an additional peak of varying intensity at 18° 2θ.

[0446] Entries 6, 9, 12, 20: The XRPD diffractograms obtained for the isolated solids were in broad agreement (see FIG. 18), with additional peaks at 10° 2θ and 13.2° 2θ observed for some samples. This XRPD diffractogram was designated Pattern C. There is no species correlation between the solvents (CH3NO2, TBME, iPrOAc, and CH3CN).

[0447] Entry 17: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern D.

[0448] Entry 18: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern E.

[0449] Entry 19: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern F.

[0450] 25°C slurry:

[0451] Entries 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 13, 14, 15, 16, 20, 21, 22: The XRPD diffractograms are all similar to those obtained for polymorph A.

[0452] Entries 6, 12, 24: The XRPD diffractograms obtained on the isolated solids were broadly consistent with pattern C (see FIG. 18).

[0453] Entry 23: XRPD analysis showed that hydrate A was formed.

[0454] Entry 17: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern D.

[0455] Entry 18: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern E.

[0456] Entry 19: The resulting XRPD diffractogram had multiple diffraction peaks (Figure 19). The XRPD diffractogram was designated pattern F.

[0457] Analyzing the results:

[0458] The XRPD diffractogram for the solid isolated at 25°C is broadly identical to the XRPD diffractogram obtained for the solid isolated at 50°C.

[0459] Patterns D, E, and F were derived from alcohols (MeOH, EtOH, and IPA). The solvated state was assumed, given that an ethanol solvate had been previously isolated during development. Although the XRPD diffractograms for the ethanol solvate are not identical, a comparison between these XRPD diffractograms gives a strong hypothesis that these more pronounced phase variations are caused by solvent entrainment, given that variations in the exact solvent level can result in varying states of order within the lattice.

[0460] XRPD patterns D, E and F (Figure 19) all bear no resemblance to the XRPD diffractogram for the hydrate (Figure 7d).

[0461] A direct comparison of the XRPD diffractograms obtained for the solids isolated at the two temperatures from MeOH, EtOH and IPA (patterns D, E and F - FIG. 19) shows matching diffractograms. The two MeOH diffractograms are similar, whereas EtOH and IPA are directly comparable.

[0462] On isolated solids, DSC analysis was performed and, if sufficient sample was available, TGA. were also performed. The solids resulting in patterns D, E, and F all featured an endotherm at approximately 170-180°C, while the others exhibited distinct thermal profiles. TGA analysis on the solid isolated from the MeOH slurry showed one long mass loss from approximately 25-190°C (3.1%). A stoichiometric methanol solvate would require 10.3% by weight of solvent. TGA analysis of the solid isolated from the EtOH slurry showed two distinct mass loss steps. The first mass loss (0.3% by weight), which occurred before 100°C, is believed to be due to water, and the second larger loss (11.5% by weight) is believed to be due to solvent. A stoichiometric ethanol solvate would require 13.9% by weight of solvent. TGA analysis of the solid isolated from the IPA slurry featured two distinct mass loss steps. The first mass loss (0.4% by weight) before 100° C. is believed to be due to water, and the second larger mass loss (13.9% by weight) is believed to be due to residual solvent. Stoichiometric IPA solvation requires 17.5% by weight of solvent.

[0463] Amorphous psilocybin slurry

[0464] To produce the amorphous material, a small sample of psilocybin (0.5 g) was dissolved in water (0.5 L, 1000 vol), polish filtered, and lyophilized. Psilocybin was recovered as an off-white fibrous material (Lot MC1368A; 412 mg, 82%, XRPD amorphous).

[0465] To visually assess the solubility of the amorphous API and to induce morphology modifications, a series of slurry digestions were performed as follows. Psilocybin (15 mg) was added to the tube. Solvent was then added (20° C., 0.3 ml, 20 vol) at ambient temperature and the suspension was stirred. Observations were made. After 1 hour of stirring, the sample was heated to 45° C. for 18 hours and observations were made. The sample was heated to 50° C. for 8 hours and observations were made. The sample was stirred at 25° C. for 72 hours and subjected to a final thermal cycle before isolation. Observations are shown in Table 35. [Table 35]

[0466] result

[0467] Most solvents returned a solid that appeared to be semi-crystalline (predominantly amorphous with a prominent reflection at approximately 18° 2θ).

[0468] Equilibration in MeCN restored the true amorphous form.

[0469] Polymorph B was reverted from chlorobutane, nitromethane and IPA (Figures 20 and 22).

[0470] Pattern D isolated from MeOH in the polymorph A slurry experiment discussed above was returned from EtOH equilibration, whereas MeOH in this study returned a semi-crystalline solid.

[0471] Solids similar to pattern A were recovered from water, THF:water and IPA:water (4:1).

[0472] A solid similar to Pattern D was recovered from EtOH:water (4:1), confirming the finding of isolation of Pattern D from EtOH alone.

[0473] A solid similar to pattern E was recovered from chloroform.

[0474] From the solvents investigated, true polymorphs A or A' were not isolated after extended equilibration and thermal aging of amorphous psilocybin. Example 12 - Formulation development.

[0475] An initial series of experiments was carried out using formulations as set forth below in Table 36. The objective was to identify suitable single or combination bulking agents for large scale formulation. [Table 36]

[0476] The results in terms of the main physicochemical properties - flowability, blend uniformity and content uniformity of the material - are given in Table 37 below. [Table 37]

[0477] The batch (APL-117-6085-03) showed excellent blend uniformity (best, medium and worst) and excellent content uniformity across the different samples analyzed, however its flow properties (based on Carr's index) were close to the upper end and the formulation was predicted not to accommodate higher drug loads.

[0478] For this reason, many alternative formulations have been tried, with the aim of exploring other filler combinations with the aim of improving powder flowability and achieving good blend and content uniformity.

[0479] Less Compactcel compared to batch 3 (APL-117-6085-03) Formulations containing MAB and higher amounts of glidant were also tried.

[0480] These further formulations are set forth in Table 38 below. [Table 38]

[0481] The results for these batches are shown in Table 39 below. [Table 39]

[0482] APL-117-6085-05 was unable to achieve good blend uniformity and failed to meet the content uniformity criteria.

[0483] Both APL-117-6085-06 and APL-117-6085-07 showed improved powder flow, but blend uniformity for both formulations was inferior to APL-117-6085-03.

[0484] As a result, applicant has developed modified additives, more specifically, silicified additives having different particle sizes. These formulations are listed in Table 40 below. [Table 40]

[0485] Prosolv is a silicified microcrystalline cellulose and two variants were chosen to determine if particle size would affect the results. Compared to standard microcrystalline cellulose (typical size range is 80-350 microns depending on sieving), Prosolv has a finer particle size distribution, imparting increased surface area. It was hypothesized that the increased surface area could impart superior flowability and increased compaction along with improved content uniformity and stability in the formulation. The ratio of Prosolv 50 and Prosolv 90 was to produce a particle size distribution spanning both finer and coarser particles.

[0486] These results are set forth in Table 41 below. [Table 41]

[0487] It can be noted that the main parameters of content uniformity (>90%, actually >94%) and AV (<10, actually <7) are excellent, as is the consistency of blend uniformity (>95% taking into account the error).

[0488] According to a preferred embodiment of the present invention, for example, the following is provided: (Section 1) Crystalline psilocybin in the form of polymorph A or polymorph A', a. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 degrees 2θ ± 0.1 degrees 2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ [further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ]; c. An XRPD diffractogram substantially as depicted in Figure 7a or 7b; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as shown in FIG. 8a or FIG. 8b. Crystalline psilocybin in the form of polymorph A or polymorph A', characterized by one or more of: (Section 2) Item 3. The crystalline psilocybin in the form of polymorph A or polymorph A' according to item 1 above, further characterized by an endothermic event in a DSC thermogram having an onset temperature of 210-215° C. a. Peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5°2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5 °2θ ± 0.1 °2θ [further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ]; c. An XRPD diffractogram substantially as depicted in Figure 7a; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as illustrated in FIG. 8a. 3. The crystalline psilocybin in the form of polymorph A according to claim 1 or 2, characterized by one or more of the following: (Section 4) 4. The crystalline psilocybin in the form of polymorph A according to claim 3, wherein the peak at 17.5° 2θ±0.1° 2θ has a relative intensity of at least 5% compared to the peak at 14.5° 2θ±0.1° 2θ. (Section 5) a. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 degrees 2θ ± 0.1 degrees 2θ, except that the peak at 17.5 degrees 2θ ± 0.1 degrees 2θ is absent or substantially absent; b. peaks in an XRPD diffractogram at 11.5, 12.0, and 14.5 °2θ ± 0.1 °2θ, provided that the peak at 17.5 °2θ ± 0.1 °2θ is absent or substantially absent, and further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ; c. An XRPD diffractogram substantially as depicted in Figure 7b; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as shown in FIG. 8b. 3. The crystalline psilocybin in the form of polymorph A' according to claim 1 or 2, characterized by one or more of the following: (Section 6) 6. Crystalline psilocybin in the form of polymorph A' as described in paragraph 5 above, wherein any peak at 17.5° 2θ±0.1° 2θ has a relative intensity of less than 5% compared to the peak at 14.5° 2θ±0.1° 2θ. (Section 7) ii) a water content of less than 0.5% w / w; or iii) Less than 0.5% w / w loss in TGA thermogram from ambient temperature, such as 25°C to 200°C 7. The crystalline psilocybin in the form of polymorph A or polymorph A' according to any one of claims 1 to 6, further characterized by having any one of: (Section 8) having a chemical purity of greater than 97% by HPLC; and 31 4. The crystalline psilocybin in the form of polymorph A or polymorph A', according to any of the preceding paragraphs, having no single impurity greater than 1%, including phosphate as measured by P NMR and psilocin as measured by HPLC. (Section 9) 2. The crystalline psilocybin in the form of polymorph A or polymorph A' according to any of the preceding paragraphs, wherein the crystalline psilocybin is a white to off-white solid. (Section 10) 13. Crystalline psilocybin in the form of polymorph A or polymorph A' as described in any of the preceding paragraphs, comprising a spectrum consistent with any one or more of Figures 10-13. (Section 11) 9. Crystalline psilocybin in the form of polymorph A or polymorph A' according to any of the preceding paragraphs, comprising acceptance criteria for one or more quality attributes of points 6 to 13 of Table 9. (Section 12) 12. A batch of crystalline psilocybin polymorph A according to any one of claims 1 to 4 or 7 to 11, comprising at least 100 g. (Section 13) A pharmaceutical formulation comprising crystalline psilocybin in the form of polymorph A or polymorph A' as described in any of the preceding paragraphs. (Section 14) Item 14. The pharmaceutical formulation according to item 13, which is in an oral dosage form. (Section 15) 15. The pharmaceutical formulation according to claim 13 or 14, wherein the crystalline psilocybin in the form of polymorph A or polymorph A' is present in an amount to provide a dosage of 0.01 mg / kg to 1 mg / kg. (Section 16) The pharmaceutical formulation according to any one of claims 13 to 15, further comprising one or more additives. 17. The pharmaceutical formulation according to claim 16, wherein the one or more excipients comprise microcrystalline cellulose or starch. (Section 18) 17. The pharmaceutical formulation of claim 16, wherein the one or more excipients comprise silicified microcrystalline cellulose. (Section 19) 12. Crystalline psilocybin in the form of polymorph A or polymorph A' according to any one of claims 1 to 11 for use in medicine. (Section 20) 12. Crystalline psilocybin in the form of polymorph A or polymorph A' according to any one of claims 1 to 11 for use in treating central nervous system disorders. (Section 21) 12. The crystalline psilocybin in the form of polymorph A or polymorph A' according to any one of claims 1 to 11 above for use in treating drug-resistant depression. (Section 22) A method for the large-scale production of psilocybin (12) in the form of polymorph A, said method comprising subjecting psilocybin (12) to a water crystallization step together with controlled drying to produce crystalline psilocybin polymorph A as described in any one of paragraphs 1 to 4 or 7 to 11 above. A method comprising: (Section 23) 1. Crystalline psilocybin in the form of polymorph A (12A) for use in medicine. (Section 24) 1. Crystalline psilocybin in the form of polymorph A (12A) for use in treating drug-resistant depression. (Section 25) 1. A method of treating drug-resistant depression comprising administering to a subject in need thereof an effective dose of crystalline psilocybin in the form of polymorph A (12A). (Section 26) a. peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5°2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, and 17.5 °2θ ± 0.1 °2θ [further characterized by at least one additional peak at 19.7, 20.4, 22.2, 24.3, or 25.7 °2θ ± 0.1 °2θ]; c. An XRPD diffractogram substantially as depicted in Figure 7a; or d. An endothermic event in a DSC thermogram having an onset temperature of 205-220° C., substantially as illustrated in FIG. 8a. 1. A process for the large scale production of psilocybin (12) in the form of polymorph A (12A), comprising subjecting psilocybin (12) to a water crystallization process together with controlled drying to produce crystals, wherein the crystals are characterized by one or more of: (Section 27) 27. The method of claim 26, wherein the psilocybin is recrystallized in about 10-20 volumes of water, heated with stirring to a temperature of at least 70°C, polished filtered, seeded at a temperature of about 70°C, and cooled to about 5°C over a period of more than 2 hours.

Claims

1. A pharmaceutical composition for oral administration to a subject in need of treatment for drug-resistant depression, comprising: the oral dosage form comprises a plurality of substances, one of which is a psilocybin drug substance; the psilocybin drug substance comprises crystalline psilocybin characterized by peaks in an XRPD diffractogram at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1 degrees 2θ, the form of which is polymorph A; The psilocybin drug substance comprises the crystalline psilocybin having a chemical purity of greater than 97% as measured by HPLC; 31 does not contain more than 1% phosphoric acid as an individual impurity as measured by P NMR; and does not contain more than 1% psilocin as an individual impurity as measured by HPLC; any one of the plurality of substances is a diluent; A pharmaceutical composition wherein the diluent comprises pregelatinized starch.

2. The pharmaceutical composition of claim 1, wherein the Carr Index of the pharmaceutical composition is within the range of about 20% to about 21%.

3. 2. The pharmaceutical composition of claim 1, wherein the peak at 17.5±0.1 degrees 2θ has a relative intensity of at least 5% compared to the peak at 14.5±0.1 degrees 2θ.

4. The crystalline psilocybin is i) a water content of less than 0.5% w / w; or ii) less than 0.5% w / w loss in the TGA thermogram over the range from 25° C. to 200° C.

10. The pharmaceutical composition of claim 1, further characterized by having any one of:

5. 2. The pharmaceutical composition of claim 1, wherein the crystalline psilocybin has a size range of from 50 microns to 200 microns.

6. 2. The pharmaceutical composition of claim 1, wherein the crystalline psilocybin is further characterized by having an endothermic event in a DSC thermogram having a first onset temperature having a value within the range of 145° C. to 155° C. and a second onset temperature having a value within the range of 205° C. to 220° C.

7. The crystalline psilocybin is a) loss on drying of 2% w / w or less; b) a residue on ignition of less than 0.5% w / w; c) Assay of 95-103% by weight (dry basis) as determined by HPLC; d) a residual solvent content of less than or equal to 3000 ppm methanol, less than or equal to 5000 ppm ethanol, less than or equal to 720 ppm THF, and less than or equal to 890 ppm toluene as measured by HRGC; e) 31 A phosphoric acid content of 1% w / w or less as measured by P NMR; and f) Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) elemental analysis of: i. Cd less than or equal to 1.5 ppm; ii. Pb less than or equal to 1.5 ppm; iii. As less than or equal to 4.5 ppm; iv. Hg less than or equal to 9.0 ppm; v. 15 ppm or less of Co; vi. 30 ppm or less V; vii. Ni less than or equal to 60 ppm; viii. Li less than or equal to 165 ppm; and ix. Pd less than 30 ppm 10. The pharmaceutical composition of claim 1, further characterized by one or more of the following:

8. 2. The pharmaceutical composition of claim 1, wherein the crystalline psilocybin has no or substantially no peak at 10.1±0.1 degrees 2θ in the XRPD diffractogram.

9. 9. The pharmaceutical composition of claim 8, wherein the peak at 10.1±0.1 degrees 2θ has a relative intensity of less than 2% compared to the peak at 14.5±0.1 degrees 2θ.

10. 9. The pharmaceutical composition of claim 8, wherein the peak at 10.1±0.1 degrees 2θ has a relative intensity of less than 1% compared to the peak at 14.5±0.1 degrees 2θ.

11. 9. The pharmaceutical composition of claim 8, wherein the peak at 10.1±0.1 degrees 2θ is not detectable in the XRPD diffractogram.

12. 10. A method for producing crystalline psilocybin according to claim 1, comprising:

1. A method for producing crystalline psilocybin comprising subjecting pre-crystallized crystalline psilocybin to a water crystallization step, wherein said pre-crystallized crystalline psilocybin is crystallized from water by controlled drying.

13. 10. A method for producing crystalline psilocybin according to claim 1, comprising: reacting psilocin with tetrabenzyl pyrophosphate, thereby forming benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate; reacting benzyl 3-[2-(benzyldimethylazaniumyl)ethyl]-1H-indol-4-yl phosphate with hydrogen in the presence of a catalyst, thereby forming at least about 100 grams or more of psilocybin; crystallizing said psilocybin from water, thereby providing said crystalline psilocybin; 1. A method for producing crystalline psilocybin comprising: